Official Title:  A Phase 3, Open -Label, One -Year Safety Study of Ruxolitinib Cream in  
Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis  
Study ID: [REMOVED]  
Document Date:  Protocol INCB [ZIP_CODE] -315 Am 1 Version 2 30 NOV 2022  
  
 
Incyte Corporation  Page 1 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL   
Clinical Study Protocol  
 
  
INCB [ZIP_CODE] -315 
A Phase 3, Open -Label, One -Year Safety Study of Ruxolitinib Cream in 
Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermati tis  
 
Product:  Ruxolitinib  cream  
IND Number:  77,[ADDRESS_645240] Number:  2021 -006626 -44 
Phase of Study : 3 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, Delaware, [LOCATION_003]  [ZIP_CODE]  
Original  Protocol:  04 MAR 2022  
Amendment 1:  [ADDRESS_645241] their origin in the Declaration of 
Helsinki (Brazil 2013)  and conducted in a dherence to the study Protocol , applicable  Good Clinical Practices , and 
applicable laws and  country -specific re gulations , including WMO (Medical Research Involving Human Participants 
Act) and Clinical Trials Regulation (EU) No. 536/2014,  in which the study is being conducted . 
The information in this document is confidential . No part of this information may be dupli cated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written  consent . 

Incyte Corporation  Page 2 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  INVESTIGATOR 'S AGREEMENT  
I have read the INCB [ZIP_CODE] -315 Protocol  Amendment 1  (dated 30 NOV  2022 ) and a gree to 
conduct the study as outlined . I agree to maintain the confidentiality of all information received 
or developed in connection with this Protocol . 
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
Incyte Corporation  Page 3 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
INVESTIGATOR'S AGREE MENT  ................................ ................................ ................................ [ADDRESS_645242] OF ABBR EVIATIONS  ................................ ................................ ................................ .......... 8 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 10 
2. INTRODUCTION  ................................ ................................ ................................ ......17 
2.1. Background  ................................ ................................ ................................ ................. 17 
2.2. Study R ationale  ................................ ................................ ................................ ........... 17 
2.2.1.  Scientific Rationale for Study Design  ................................ ................................ ........ 18 
2.2.2.  Justification for Treatment Regimen  ................................ ................................ .......... 18 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 18 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 20 
4. STUDY DESIGN  ................................ ................................ ................................ .......21 
4.1. Overall  Design  ................................ ................................ ................................ ............ 21 
4.2. Overall Study Duration  ................................ ................................ ............................... 22 
4.3. Study Termination  ................................ ................................ ................................ ......22 
5. STU DY POPULATION  ................................ ................................ ............................. 23 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 23 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......24 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 26 
5.4. Screen Failures  ................................ ................................ ................................ ............ 26 
5.5. Replacement of Participants  ................................ ................................ ....................... 26 
6. STUDY TREATMENT  ................................ ................................ .............................. 27 
6.1. Study Treatment Administered  ................................ ................................ ................... 27 
6.1.1.  Study Treatment Application Guidance  ................................ ................................ .....28 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 29 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ........ [ADDRESS_645243] to Follow -Up................................ ................................ ................................ .......36 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 37 
8.1. Administrative and General Procedures  ................................ ................................ .....37 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 37 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..38 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 38 
8.1.4.  Distribution of Reminders and eDiaries  ................................ ................................ .....39 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 39 
[IP_ADDRESS].  Demographics and General Medical History  ................................ ............................. 39 
[IP_ADDRESS].  Disease Characteristics and Treatment History  ................................ .......................... 39 
8.2. Efficacy Assessments  ................................ ................................ ................................ .40 
8.2.1.  Health Economics  ................................ ................................ ................................ .......40 
8.2.2. Percent Body Surface Area Affected by [CONTACT_25792]  ................................ .......40 
8.2.3.  Investigator's Global Assessment  ................................ ................................ ............... 40 
8.2.4.  Itch Numerical Rating Scale  ................................ ................................ ....................... 41 
8.2.5.  Eczema Area and Severity Index  ................................ ................................ ................ 41 
8.3. Safety Assessments  ................................ ................................ ................................ .....41 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 41 
8.3.2.  Physical Examinations  ................................ ................................ ................................ 42 
[IP_ADDRESS].  Comprehensive Physical Examination  ................................ ................................ .......42 
[IP_ADDRESS].  Targeted Physical Examination  ................................ ................................ .................. 42 
8.3.3.  Vital Signs, Height, and Weight  ................................ ................................ ................. 43 
Incyte Corporation  Page 5 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  8.3.4.  Electrocardiograms  ................................ ................................ ................................ .....43 
8.3.5.  Laboratory Assessments  ................................ ................................ ............................. 43 
[IP_ADDRESS].  Pregnancy Testing  ................................ ................................ ................................ ......44 
[IP_ADDRESS].  Serology  ................................ ................................ ................................ ...................... 44 
8.4. Pharmacokinetic Assessments  ................................ ................................ .................... 45 
8.5. Pharmacodynamic and Translational Assessments  ................................ .................... 45 
8.6. Unscheduled Visits  ................................ ................................ ................................ .....46 
8.7. End of Treatment and/or Early Termination  ................................ .............................. 46 
8.8. Follow -Up ................................ ................................ ................................ ................... 46 
8.8.1.  Safety Follow -Up ................................ ................................ ................................ ........ 46 
9. ADVERSE EVENTS: DEFI NITIONS AND PROCEDUR ES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 47 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 47 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 48 
9.3. Recording and Follow -Up of Adverse Events and /or Serious Adverse Events  ......... [ADDRESS_645244] Complaints  ................................ ................................ ................................ ....53 
9.10.  Treatment of Excessive Use  ................................ ................................ ....................... 53 
10. STATISTICS  ................................ ................................ ................................ .............. 54 
10.1.  Sample Size Determination  ................................ ................................ ........................ 54 
10.2.  Populations for Analyses  ................................ ................................ ............................ 54 
10.3.  Level of Significance  ................................ ................................ ................................ ..54 
10.4.  Statistical Analyses  ................................ ................................ ................................ .....54 
10.4.1.  Primary Analysis  ................................ ................................ ................................ ........ 54 
10.4.2.  Secondary Analyses  ................................ ................................ ................................ ....55 
[IP_ADDRESS].  Clinical Laboratory Tests  ................................ ................................ ........................... 55 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 55 
10.4.3.  Pharmacokinetic Analyses  ................................ ................................ .......................... 55 
10.4.4.  Exploratory Efficacy Analyses  ................................ ................................ ................... 56 
Incyte Corporation  Page 6 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  10.4.5.  Exploratory Analysis of Relationship Between Hematology Laboratory 
Results and Trough Ruxolitinib Concentrations  ................................ ......................... 56 
10.5.  Interim Analysis  ................................ ................................ ................................ .......... 57 
11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..58 
11.1.  Investigator Responsibilities  ................................ ................................ ....................... 58 
11.1.1.  Identification of the Coordinating Principal Investigator  ................................ ........... 59 
11.2.  Data Management  ................................ ................................ ................................ .......59 
11.3.  Data Quality Assurance  ................................ ................................ .............................. 61 
11.4.  Data Privacy and Confidentiality of Study Records  ................................ ................... 61 
11.5.  'Financial Disclosure  ................................ ................................ ................................ ...[ADDRESS_645245] OF TABLES  
Table  1: Primary and Secondary Objectives and Endpoints  ................................ ..................... 10 
Table  2: Key Stu dy Design Elements  ................................ ................................ ....................... 10 
Table  3: Schedule of Activities: Continuous Treatment Period  ................................ ............... 12 
Table  4: Schedule of Activities: Long -Term Safety Period  ................................ ...................... 15 
Table  5: Objectives and Endpoints  ................................ ................................ ........................... 20 
Table  6: Study Treatment Information  ................................ ................................ ..................... 27 
Table  7: Guidelines for Interruption and Restarting of Study Cream Due to 
Laboratory  Abnormalities  ................................ ................................ ........................... 31 
Table  8: Investigator's Global Assessment  ................................ ................................ ............... 40 
Table  9: Required Laboratory Analytes  ................................ ................................ .................... 44 
Table  10: Pharmacokinetic Blood and Saliva Sample Timing  ................................ ................... 45 
Table  11: Populations for Analysis  ................................ ................................ ............................. 54 
Table  12: Summary of Primary Endpoint Analyses  ................................ ................................ ...55 
Table 13:  Summary of Secondary Endpoint Analyses  ................................ ............................... 56 
Table  14: Summary of Exploratory Endpoint Analyses  ................................ ............................. [ADDRESS_645246] OF FIGURES  
Figure  1: Study Design Schema  ................................ ................................ ................................ .11 
Figure 2:  Study Cream Application Using a Fingertip  ................................ .............................. [ADDRESS_645247] continuous treatment  
CTCAE  Common Terminology Criteria for Adverse Events  
DVT deep vein thrombosis  
EASI  Eczema Area and Severity Index  
EASI75  ≥75% improvement in EASI scor e 
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EOS  end of study  
EOT  end of treatment  
ET early termination  
FAS full analysis set  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clini cal Practice  
GDPR  General Data Protection Regulation  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
HIV human immunodeficiency virus  
HRT  hormone replacement therapy  
IB Investigator 's Brochure  
Incyte Corporation  Page 9 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Abbreviations and 
Special Terms  Definition  
ICF informed consent form  
ICH Interna tional Council for Harmoni sation of Technical Requirements for 
Pharmaceuticals for Human Use  
ID identification  
IEC independent ethics committee  
IGA Investigator 's Global Assessment  
IGA-TS Investigator 's Global Assessment Treatment Success (IGA score of  0 or 1 with 
≥ 2 grade improvement from baseline)  
IRB institutional review board  
IRT interactive response technology  
Itch NRS  Itch Numerical Rating Scale  
JAK Janus kinase  
LTS long-term safety  
MedDRA  Medical Dictionary for Regulatory Activities  
MPV  mean platelet volume  
PD pharmacodynamic (s) 
PDE4  phosphodiesterase 4  
PE pulmonary embolism  
PK pharmacokinetic (s) 
RSI Reference Safety Information  
SAE  serious adverse event  
SoA schedule of activities  
SOP standard operating procedure  
SPF sun protectio n factor  
STD  standard deviation  
TEAE  treatment -emergent adverse event  
ULN  upper limit of normal  
UV ultraviolet  
WOCBP  woman of childbearing potential  
Incyte Corporation  Page 10 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  1. PROTOCOL SUMMARY  
Protocol Title:  A Phase 3, Open-Label, One -Year Safety Study o f Ruxolit inib Cream i n 
Adolescents (Ages ≥ 12 Years t o < 18 Years) With Atopic Derm atitis  
Protocol Number:  INCB [ZIP_CODE] -315  
Objectives and Endpoints : 
Table  1 presents the primary and secondary objectives and endpoints.  
Table  1: Primary and Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the long -term safety and tolerability of 
ruxolitinib cream in adolescents with AD. Incidence of TEAEs, assessed by [CONTACT_501013], 
frequency, and severity of AEs.  
Secondary  
To further evaluate the long -term safety and tolerability 
of ruxolit inib cream in adolescents with AD. Changes in vital signs, height, weight, and laboratory 
data for hematology and serum chemistry.  
To characterize the PK of ruxolitinib cream in 
adolescents with AD. Trough concentrations of ruxolitinib at each 
postbaselin e visit.  
Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table.  
Table  2: Key Study Design Elements  
Study  Phase  Phase [ADDRESS_645248] 2 years, a  total IGA score of 2 or 3, and BSA involvement of 3% to 20%  
(excluding the scalp) . 
Number of Participants  Approximately 100 participants will be enrolled.  
Study  Design  Open -label, single -group, LTS study.  
Estimated Durati on of 
Study  Participation  Participants will take part  in the study for up to approximately 6 0 weeks: [ADDRESS_645249]/Data Monitoring 
Committee  No 
Coordinating Principal 
Investigator  [INVESTIGATOR_500984] 11 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Treatment Groups and Duration:  
This is a Phase 3, open -label, 1-year safety study of ruxolitinib cream in approximately 
100 adolescents (ages ≥ 12 years to < 18 years) with AD whose disease is not adequately 
controlled with topi[INVESTIGATOR_500985] (see study 
design schema in Figure  1). 
All participants will apply ruxolitinib cream at the FDA -approved strength (1.5%) BID , starting 
with an [ADDRESS_645250] period during which participants will treat all baseline AD lesions BID, 
regardle ss of whether or not the lesion(s) improve, followed by a [ADDRESS_645251] a safety follow -up visit 30 to 37 days f ollowing the end of treatment 
(Week 52/EOT2 or ET) to evaluate safety and duration of response  except for participants who 
have been in an observation/no treatment cycle  with a total IGA score of 0 from Week 48 or 
earlier until Week 52, for whom the Week 52/EOT2 visit will also count as the safety follow -up 
visit. 
Figure  1 presents the  study design schema, and Table  3 (CT period) and Table  4 (LTS period) 
present  the SoA. 
Figure  1: Study Design Schema  
 
Adherence to the study design requirements, including those specified in the SoA, is essen tial 
and required for study conduct.  

Incyte Corporation  Page 12 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table  3: Schedule of A ctivitie s: Continuous Treatment Period  
Visit Day (Range)  Screening  CT 
Notes  Days  −28 
to -1 Day 1  
(Baseline)  Week 2  
(± 3 d)  Week 4  
(± 3 d)  Week 8/EOT1a 
or ET  
(± 3 d)  
Administrative p rocedures  
Informed consent (including assent)  X     Section  8.1.[ADDRESS_645252] IRT  X X X X X Section  8.1.3   
Inclusion/exclusion criteria review  X X    Section  5 
Demography and general medical history  X     Section  [IP_ADDRESS]   
Relevant AD medical and  treatment history  X     Section  [IP_ADDRESS]   
Prior/concomitant medications and procedures  X* X X X X Section  6.6  
*For prior medications that require a 4 -week washout 
period  (Section  5.2, Exclusion C riterion 5 b), a 35-day 
screening period is allowed.  
Apply study cream  at site   X X X X* Section  6.1.1 ; at the Day [ADDRESS_645253] (morning) application at the site under 
direct site staff supervision.  At all other visits, the 
participant may apply either of the [ADDRESS_645254] 4 hours since the previous 
dose was applied (see Section  8.4). 
*Not applicable to the Week 8 visit if IGA score = 0 or 
to the ET visit.  
Weigh/dispense study cream  and distribute 
reminder   X X X X* Section  6.1.1  and Section  8.1.4  
*Not applicable to the ET visit.  
Collect/weigh returned study cream  and 
review study cream  eDiary compliance    X X X Section  6.1.1 and Section  8.1.4  
Assess study cream  application  compliance    X X X Section  6.4  
Assess I tch NRS eDiary compliance  eDiary compliance should be assessed routinely  Section  8.2.4  
Incyte Corporation  Page 13 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table  3: Schedule of Activities: Continuous Treatment Period  (Continued)  
Visit Day (Range)  Screening  CT 
Notes  Days −28 
to -1 Day 1  
(Baseline)  Week 2  
(± 3 d)  Week 4  
(± 3 d)  Week 8/EOT1a 
or ET  
(± 3 d)  
Safety assessments  
AE assessments and targeted physical 
examination  X X X X X* Section  8.3.1  and Section  [IP_ADDRESS] ; body systems with 
symptoms should be physically examined.  
*Targeted physical exam ination  not performed  at ET 
visit.  
Comprehensive physical examination  X    X* Section  [IP_ADDRESS]   
*For the ET visit only.  
Body height and weight   X   X Section  8.3.3 ; height should be measured with a 
stadiometer and recorded.  
Vital signs  X X X X X Section  8.3.3 ; vital signs should be  taken before blood 
sampling and other procedures.  
12-lead ECG  X     Section  8.3.4 ; 12-lead ECG performed within 2 months 
before baseline is acceptable.  
Efficacy a ssessments  
%BSA affected by [CONTACT_22802]  X X X X X* Section  8.2.2  
*At Week 8, to qualify for the LTS period, the %BSA 
range must be  0% to ≤ 20%.  
Total IGA and facial IGA  X X X X X* Section  8.2.3   
*At Week 8, there are no restrictions on IGA score to 
qualify for the LTS period.  
EASI  X X X X X Section  8.2.[ADDRESS_645255] period (night before Week 
8 visit).  Section  8.2.4   
Incyte Corporation  Page 14 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table  3: Schedule of Activities: Continuous Treatment Period  (Continued)  
Visit Day (Range)  Screening  CT 
Notes  Days −28 
to -1 Day 1  
(Baseline)  Week 2  
(± 3 d)  Week 4  
(± 3 d)  Week 8/EOT1a 
or ET  
(± 3 d)  
Laboratory a ssessments  
Serum chemistries  X X* X X X Section  8.3.5   
*Perform Day [ADDRESS_645256] is > 
2 weeks.  
Hematology  X X* X X X Section  8.3.5  
*Perform Day [ADDRESS_645257] is 
> 2 weeks.  
Serology  X     Section  [IP_ADDRESS] ; HIV antibody . 
Pregnancy testing  X* X  X X Section  [IP_ADDRESS]   
*WOCBP  will have a serum  pregnancy  test at 
screening and a urine test at all other visits. A positive 
urine test must be confirmed with a serum test.  
PK blood  and saliva sampling (trough)    Blood  
and 
saliva  Blood  
and 
saliva  Saliva  only Section  8.4; collected prior to study cream  application 
at the clinic; the time of prior study cream  application 
is to be recorded in the eCRF.  
Blood samples must not be drawn from an area that has 
been t reated with study cream (or participants must not 
apply study cream from  the previous application of 
study cream on the immediate body area where blood 
is to be drawn ). 
a All assessment s for the Week 8/EOT1 visit must be performed before participants may enter the LTS period.  
Incyte Corporation  Page 15 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table  4: Schedule of Activities:  Long -Term Safety Period  
Visit Day (Range)  LTS  Safety Follow -Up 
Notes  Weeks 12, 20, 
28, 36, and 44 
(± 7 d)  Week 52/EOT2 
or ET  
(± 7 d)  Unscheduled 
Visits  30-37 d A fter 
Week 52/EOT2 
or ET V isita 
Administrative p rocedures  
Contact [CONTACT_12067]  X X X X Section  8.1.3  
Prior/concomitant medications and procedures  X X X X Section  6.6 
Apply study cream  at site  X    Section  6.1.1 ; only for participants with 
active AD lesions at time of visit.  
Weigh/dispense study cream  and distribute 
reminder  X    Section  6.1.[ADDRESS_645258]/weigh returned study cream  and review 
study cream  eDiary compliance  X X   Section  6.1.[ADDRESS_645259] start and end dates of treatment cycle(s)  X X   Section  6.1; the start/end date will have been 
recorded by [CONTACT_2299]. The end date 
should be 3 days after lesions clear; however, 
if this 3 -day window i s during a study visit 
and total IGA score = 0, stop treatment and 
record the date of the study visit as the 
treatment cycle end date.  
Assess  study cream  application compliance  X X   Section  6.4 
Assess Itch  NRS eDiary compliance  eDiary compliance should be assessed routinely   Section  8.2.4  
Safety a ssessments  
AE assessments and targeted physical examination  X X* X X Section  8.3.1  and Section  [IP_ADDRESS] ; body 
systems with symptoms should be physically 
examined.  
*Targe ted physical exam ination  not 
performed  at the Week 52/EOT2  or ET visit.  
Comprehensive physical examination   X   Section  [IP_ADDRESS]   
Body height and weight  X* X   Section  8.3.3 ; height should be measured 
with a stadiometer and recorded  
*Week 28 only.  
Vital signs  X X X X Section  8.3.3 ; vital signs should be  taken 
before blood/saliva sampling and other 
procedures.  
Incyte Corporation  Page 16 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table  4: Schedule of Activities:  Long -Term Safety Period  (Continued)  
Visit Day (Range)  LTS  Safety Follow -Up 
Notes  Weeks 12, 20, 
28, 36, and 44 
(± 7 d)  Week 52/EOT2 
or ET  
(± 7 d)  Unscheduled 
Visits  30-37 d After 
Week 52/EOT2 
or ET V isita 
Disease severity a ssessments  
%BSA affected by [CONTACT_22802] X X X X Section  8.2.[ADDRESS_645260] 
application of study cream  during  the LTS period.   Section  8.2.4  
Laboratory a ssessments  
Serum chemistries  X X X X Section  8.3.5  
Hematology  X X X X Section  8.3.5  
Pregnancy testing  X X X X Section  [IP_ADDRESS] ; WOCBP  will have a urine 
test at all visits. A positive urine test must be 
confirmed by a serum test.  
PK saliva sampling (trough)  X*/† X†/‡   Section  8.4 
*Collected prior to study cream  application 
at the clinic.  
†The time of prior study cream  application is 
to be recorded in the eCRF.  
‡Not to be collected at  the ET visit . 
a Except for participants who have been in an observation/no treatment cycle with a  total IGA score of 0 (clear) from Week 48 or earlier until Week 52; such participants should 
complete the Week 52/EOT 2 visit  and this will also count as the safety follow -up visit.  
 
Incyte Corporation  Page 17 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  2. INTRODUCTION  
2.1. Background  
Atopic dermatitis is a chronic, recurring, inflammatory, and highly pruritic skin condition that 
affects up to 25% of children and up to 12% of adults worldwide ( Eichenfield et al 2014 , Hanifin 
et al 2007 , Harrop et al 2007 , Rönmark et al 2012 , Vinding et al 2014 ) and is one of the most 
common dermatoses encountered by [CONTACT_501014] . Although not 
life-threatening, patients with AD are at higher risk for the development of other potentially 
life-threatening disorders such as  asthma and/or food allergy ( Spergel  2010 ). According to the 
recent Global Burden of Disease project, AD is one of the [ADDRESS_645261] disability ranking of all nonmalignant sk in diseases ( Hay et al 2014 ). 
Despi[INVESTIGATOR_249669] a number of treatment options, there is still a significant medical need 
for safe topi[INVESTIGATOR_500986] . Moderate to potent topi[INVESTIGATOR_500987] -known safety restrictions limiting their use to 4 and 8 weeks, 
respectively.  In addition, a PDE4 inhibitor, 2% crisaborole (Eucrisa®) ointment, is approved in 
the US for patients aged [ADDRESS_645262]  efficacy  (Eucrisa  2020 ).  
Janus kinases  are intracellular signaling enzymes that act downstream of key proinflammatory 
cytokines known to promote the pathogenesis  of AD . Ruxolitinib (INCB018424) is a potent and 
selective JAK1 and JAK2 inhibitor that is currently approved for use in tablet form for the  
treatment of patients with  myelofibrosis and polycythemia vera in multiple countries and acute 
and chronic graft -versus -host disease in the US. Recent studies suggest that JAK inhibition may 
have antipruritic effects by [CONTACT_501015] n erve fibers and may offer a novel 
therapeutic approach with dual anti -inflammatory and antipruritic properties.  
Ruxolitinib cream is a topi[INVESTIGATOR_500988] -term and nonconti nuous chronic treatment of mild to  moderate AD 
in nonimmunocompromised patients 12 years of age and older whose disease is not adequately 
controlled  with topi[INVESTIGATOR_500985]  
(Opzelura™ 2022 ). This approval was based on data from 2 Phase 3 studies in adolescents and 
adults with AD (INCB [ZIP_CODE] -303 and -304; Papp et al 2021 ) and supported by [CONTACT_501016] a 
Phase 2 study in adults with AD (INCB [ZIP_CODE] -206; Kim et al 2020a , Kim et al 202 0b). Refer to 
the IB for additional details . 
2.2. Study Rationale  
The primary  purpose of this study is to collect additional long-term safety  data regarding the 
types and frequencies of TEAEs occurring in adolescents with AD who are treated with 
ruxolitinib 1.5% cream BID. In the Phase 3 studies, 114 adolescents were treated  with ruxolitinib 
1.5% cream BID , and the safety profile was similar to  that in adults. This is a Post -Marketing 
Requirement study for the FDA.  
Incyte Corporation  Page 18 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  2.2.1.  Scientific Rationale for Study Design  
As the intent of this study is to further assess the safety of ruxolitinib 1.5% cream BID in 
adolescents with AD in addition to what was studied in the Phase 3 studies, INCB [ZIP_CODE] -303 
and INCB [ZIP_CODE] -304, the study population has been based on that in the Phase 3 studies, namely 
adolescents aged ≥ 12 to <  [ADDRESS_645263] 2 years and affecting 3 % to 20% 
BSA (excluding the scalp) plus a  total IGA score of 2 or 3.  
In addition, given the recent concerns about the potential thromboembolic and cancer risks of 
oral JAK inhibitors that are currently approved as treatments for rheumatoid arthritis ( Olumiant 
2021, Xeljanz 202 1), the exclusion  criteria have been augmented where necessary to exclude 
anyone with current or a history of venous thromboembolism (DVT or PE), major adverse 
cardiovascular events , or malignancies.  
The prima ry and secondary objectives and endpoints focus on further assessing the safety and 
tolerability of ruxolitinib 1.5% cream BID in adolescents through assessment of TEAEs, vital 
signs (in particular height and weight), laboratory data for hematology and ser um chemistry, and 
PK (trough concentrations of ruxolitinib).  
2.2.2.  Justification for Treatment Regimen  
All participants will apply ruxolitinib cream at the FDA -approved strength (1.5%) and 
application frequency (BID) using the same treatment paradigm as the Phas e [ADDRESS_645264] period during which  participants will treat all baseline AD 
lesions, regardless of whether or not the lesion(s) improve, followed by a 44 -week LTS period 
during which  participants will only treat active AD lesions. Modifications to the treatment 
regimen will not be allowed, as in the Phase 3 AD studies (refer to Section 6.5, Dose 
Modifications , for more details) . 
2.3. Benefit/Risk Assessment  
In the Phase 3 AD studies , ruxolitinib 1.5% cream BID rapi[INVESTIGATOR_500989], being statistically significantly  superior to 
vehicle cream BID at the end of the vehicle -controlled period (Week 8) for IGA -TS, EASI75, 
and ≥ [ADDRESS_645265] of ruxolitinib 1.5% cream 
BID showed a rapid onset with evidence of a treatment eff ect on daily Itch NRS scores as early 
as Day 1 (ie, within [ADDRESS_645266] application of study cream ). The disease course 
(assessed by [CONTACT_501017] %BSA affected by [CONTACT_501018]  8 through 52) 
was well -controlled throughout th e entirety of the LTS period of the study. The treatment effects 
of ruxolitinib 1.5% cream BID on IGA -TS, EASI75, and Itch NRS score were consistently 
observed acros s both adult and adolescent sub groups.  
Safety data from the Phase 3 AD studies demonstrated  that use of ruxolitinib 1.5% cream BID 
continuously for 8 weeks followed by [CONTACT_457481] (44 weeks) intermittent use was safe and 
well-tolerated. The TEAEs were generally Grade [ADDRESS_645267] infection. Frequencies of these events were within the 
expected range for the general AD population. There were no meaningful differences in the 
TEAE profile of ruxolitinib 1.5% cream BID between the adult and adolescent subgroups.  
Incyte Corporation  Page 19 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Results from  dermal safety studies in healthy adult participants (INCB [ZIP_CODE] -104, -105, -106, 
-107, and -108) to evaluate local tolerability demonstrated that ruxolitinib 1.5% cream did not 
cause sensitization and was only slightly irritating under exaggerated testin g conditions 
(occlusive application). In addition, ruxolitinib 1.5% cream was not phototoxic and did not 
induce photosensitization. This was further confirmed by [CONTACT_165894]  3 (INCB [ZIP_CODE] -303 and 
-304) safety data where ruxolitinib 1.5% cream BID was well -tolerated at the application sites 
with infrequently reported application site reactions. The most frequently reported application 
site reaction events were application site pain ( lowest level terms  were primarily application site 
burning or application sit e stinging) and application site pruritus; each of these events occurred 
in a lower proportion of participants in the ruxolitinib 1.5% cream BID treatment group 
(application site pain , 0.7%; application site pruritus , 0.6%) compared with the vehicle cream 
treatment group (application site pain , 4.8%; application site pruritus , 2.8%) during the 8 -week, 
vehicle -controlled  period, which may be attributable to worsening of the underlying disease in 
the absence of active drug treatment.  
The overall benefit/ risk assessment of ruxolitinib 1.5% cream BID favors its use in both 
adolescent and adult patients with AD affecting areas up to and including 20% BSA.  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of ruxo litinib cream may be found in the IB. 
Incyte Corporation  Page 20 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  3. OBJECTIVES AND ENDPOINTS  
Table  5 presents the objectives and endpoints.  
Table  5: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the long -term safety and tolerability 
of ruxolitinib cream in adolescents with AD. Incidence of TEAEs, assessed by [CONTACT_501019], frequency, and severity of AEs.  
Secondary  
To further evaluate the long -term safety and 
tolerability of ruxolitinib cream in adolescents 
with AD. Changes in vital signs, height, weight, and 
laboratory data for hematology and serum 
chemistry.  
To characterize  the PK of ruxolitinib cream in 
adolescents with AD. Trough concentrations of ruxolitinib at each 
postbaseline visit.  
Exploratory  

Incyte Corporation  Page 21 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  4. STUDY DESIGN  
4.1. Overall Design  
This is a Phase 3, open -label, 1-year safety study of ruxolitinib cream in adolescents (ages 
≥ 12 years to < 18 years) with AD whose disease is not adequately controlled with topi[INVESTIGATOR_500990] (see study design schema in 
Figure  1). The study will be conducted at approximately 40 sites in North America and Europe.  
Approximately 100 participants with a diagnosis of AD (as defined by [CONTACT_85811] 
[1980 ] criteria) with a duration of  disease of at least 2 years, a total  IGA score of 2 or 3, and 
%BSA affected by [CONTACT_501020] 3% to 20% (ex cluding the scalp) will be enrolled.  
All participants will apply ruxolitinib cream at the FDA -approved strength (1.5%) BID using the 
same treatment paradigm as the INCB [ADDRESS_645268] period during  which participants will treat all baseline AD lesions, regardless 
of whether or not the lesion(s) improve, followed by a 44 -week LTS period during which 
participants will only treat active AD lesions.  
Participants who complete the Week 8 assessments with no safety concerns and with %BSA 
affected by [CONTACT_501021] 20% will continue into the LTS period.  
During the LTS period (ie, starting at the Week 8 visit), the treatment regimen will continue to 
be ruxolitinib 1.5% cream BID; however , participants wi ll only treat active AD lesions. 
Participants will have the next study visit at Week 12, and then subsequent study visits will occur 
every 8  weeks until the end of the study (44 weeks total in the LTS period and 52 weeks total in 
the study). At those study  visits, AD lesions will be evaluated by [CONTACT_501022] ( total IGA score ≥ 1) or can otherwise 
(re)enter the observation/no treatment cycle ( total IGA score = 0).  Refer to Section  6.1 for 
further details.  
Participants will be assessed for the safety and tolerability o f ruxolitinib cream throughout the 
study by [CONTACT_501013], frequency, and severity of AEs ; performing physical examinations ; 
measuring vital signs, in cluding  height and weight ; and conducting clinical laboratory 
assessments, as outlined in the SoA (se e Table  3 [CT period] and Table  4 [LTS period]).  In 
addition, the trough ruxolitinib concentration will be measured at various timepoints throughout 
the study (see Table  3 [CT period]  and Table  4 [LTS period] ), and its relationship with select 
hematology parameters such as platelet count, MPV, hemoglobin  level,  and neutrophil count will 
be assessed.  
Several exploratory disease severity assessments will be conducted throughout the study (see 
Table  3 [CT period]  and Table  4 [LTS period] ) to evaluate the long -term efficacy of ruxolitinib 
cream, namely  
 
All par ticipants will have a safety follow -up visit 30 to 37 days f ollowing the end of treatment 
(Week 52/EOT2 or ET) to evaluate safety and duration of response  except for participants who 
have been in an observation/no treatment cycle  with a total IGA score of 0 from Week 48 or 
earlier until Week 52 , for whom the  Week 52/EOT2 visit will also count as the safety follow -up 
visit. See Section  8.8.1  for further details . 

Incyte Corporation  Page 22 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Figure  1 presents the study design schema, and Table  3 (CT period) and Table  4 (LTS period) 
present the SoA. 
4.2. Overal l Study Duration  
The study begins when the first participant signs the study ICF. The end of the study is defined 
as the date of the last visit of the last participant in the study or the date  that the last participant 
has discontinued study cream  and has completed applicable safety follow -up assessments or is 
lost to follow -up. 
Participants will participate in the study for a duration of up to approximately 6 0 weeks:  [ADDRESS_645269] period, 44 weeks in the LTS period, and  30 days in 
the safety follow -up period (see Figure  1). 
A participant is considered to have completed the study  if they have  completed all study visit s, 
including the safety follow -up visit .  
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract . The investigator is to notify the IRB /IEC of the study 's 
completion or early termination  in writing , send a copy of the notification to the sponsor or 
sponsor 's designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study electively or if required by a regulatory agency . In the 
event of significant safety findings, the study will be terminated.  If the study is terminated 
prematurely, the sponsor will notify the investigators, the IRBs and IECs, and the regulatory 
bodies of the decision an d reason for termination of the study . 
Incyte Corporation  Page 23 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participant  safety . Therefore, 
adhe rence to the criteria as specified in the Protocol is essential . Prospective approval of Protocol 
deviations to recruitment and enrollment criteria, also known as Protocol waivers or exemptions, 
are not permitted.  
5.1. Inclusion Criteria  
Participants are eligib le to be included in the study only if all of the following criteria apply:  
1. Adolescents  aged ≥ 12 years to < 1 8 years (at the screening visit).  
2. A diagnosis of AD as defined by [CONTACT_85811] ( 1980 ) criteria.  
3. Duration of AD of at least 2 years.  
4. Total IGA score of 2 to 3 at the screening and baseline visits . 
5. Percent BSA (excluding the scalp) with AD involvement of 3% to 20% at the screening 
and baseline visits.  
6. Atopic dermat itis not adequately controlled with oth er topi[INVESTIGATOR_500991].  See Section  [IP_ADDRESS]  for further details.  
7. Agree to discontinue all agent s used to treat AD from screening through the final 
follow -up visit.  
8. Willingness to avoid pregnancy or fathering children based on the criteria below.  
a. Male participants with reproductive potential  must agree to take appropriate 
precautions to avoid fatheri ng children from screening throug h 90 days (a 
spermatogenesis cycle)  after the last application  of ruxolitinib cream and must refrain 
from donating sperm during this period.  Permitted methods in preventing pregnancy 
(see Appendix  A) should be communicated to the participants and their understanding 
confirmed . 
b. Female participants who are WOCBP must have a negative serum pregnancy test at 
screening and a negative urine pregnancy test before the first application of 
ruxolitinib cream on Day [ADDRESS_645270] agree to take appropriate precautions to avoid 
pregnancy from screening through 30 days (1  menstrual cycle) after the last 
application of ruxolitinib cream and must refrain from donating oocytes during this 
period.  Permitted methods in preventing pregnancy (see Appendix  A) should be 
communicated to the participants and their understanding confirmed.  
c. A female participant not considered to be of childbearing potential as defined in 
Appendix  A is eligible.  
9. Ability to comprehend and willingness to sign an ICF or written informed consent of the  
parent(s) or legal guardian (s) and written assent from the participant when possible.  
Note: Participants who become legal adults during  the study will be asked for their signed 
consent to continue the study, and in the event of lack thereof, will be discontinued from 
further participation.  
Incyte Corporation  Page 24 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. An unstable course of AD (spontaneously improving or rapi[INVESTIGATOR_166462]) as 
determined by [CONTACT_99824] 4 weeks prior to baseline.  
2. Concurrent conditions and history of other diseases:  
a. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, 
Wiskott -Aldrich syndrome).  
b. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline.  
c. Active acute bacterial, fungal, or viral skin infectio n (eg, herpes simplex, herpes 
zoster, chickenpox) within 1 week before baseline.  
d. Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton 
syndrome), pi[INVESTIGATOR_371], or extensive scarring that, in the opi[INVESTIGATOR_871], 
may interfere with the evaluation of AD lesions or compromise participant safety.  
e. Presence of AD lesions only on the hands or feet without prior history of involvement 
of other classic areas of involvement such as the face or the flexural folds.  
f. Other types of eczema.  
g. Current or history of hepatitis B or C virus infection . 
3. Any current and/or history of serious illness or medical, physical, or psychiatric 
condition(s) that, in the investigator 's opi[INVESTIGATOR_1649] , would interfere with full participation in 
the study, in cluding application of study cream  and attending required study visits; pose a 
significant risk to the participant; or interfere with interpretation of study data. For 
example:  
a. Clinically significant or uncontrolled cardiovascular disease, including unstab le 
angina, acute myocardial infarction or stroke within 6 months from Day 1 of study 
cream  application, [LOCATION_001] Heart Association Class III or IV congestive heart 
failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood 
pressure > 150 /90 mm  Hg) unless approved by [CONTACT_7195]/sponsor.  
b. Current  and/or history of malignancy  in the 5 years preceding the baseline visit, 
except for adequately treated, nonmetastatic nonmelanoma skin cancer.  
c. Current and/or history of arterial or venous thrombosis, including DVT  and PE. 
d. Current and/or history of active tuberculosis or current and/or history of latent 
tuberculosis unless adequately treated.  
4. Any of the following clinical laboratory test results at screening:  
a. Hemoglobin < 100 g/L (< 10 g/dL)  
b. Liver function tests:  
− AST or ALT ≥ 2.5 × ULN  
− Total bilirubin > 1.5 × ULN with the exception of Gilbert disease .  
c. Estimated glomerular filtration rate  < 30 mL/min/1.73 m2 (using the CKD  
Epi[INVESTIGATOR_500992]).  
d. Positive serology test results for HIV antibody.  
e. Any other clinically significant laboratory result that, in the opi[INVESTIGATOR_1070], poses a significant risk to the participant . 
Incyte Corporation  Page 25 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  5. Use of  any of the following treatments within the indicated washout period before 
baseline:  
a. 5 half -lives or 12 weeks , whichever is longer – biologic agents (eg, dupi[INVESTIGATOR_12458]). For 
biologic agents with washout periods  longer than 12 weeks  (eg, rituximab), consult 
the medical monitor.  
b. 4 weeks  – systemic corticosteroids or adrenocorticotropic hormone a nalog ues, 
cyclosporin e, methotrexate, azathioprine, or other systemic immunosuppressive or 
immunomodulating agents (eg, mycophenolate or tacrolimus).  
c. 2 weeks  – immunizations with live -attenuated vaccines; sedating antihistamines, 
unless on long -term stable  regimen (nonsedating antihistamines are permitted).  
Note: Live-attenuated vaccines are not recommended during the CT period.  
Note:  COVID -19 vaccination is allowed.  
d. 1 week  – use of other topi[INVESTIGATOR_117928] (other than bland emollients, eg, 
Aveeno® creams, ointments, sprays, soap substitutes ), such as topi[INVESTIGATOR_235972] 
(eg, doxepin cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar 
(shampoo), antibiotics, or antibacterial cleansing body wash/soap.   
Note: Diluted sodium hy pochlorite "bleach " baths are allowed as long as they do not 
exceed 2 baths per week and their frequency remains the same throughout the study.  
6. Previously received systemic or topi[INVESTIGATOR_73209] (eg, ruxolitinib, tofacitinib, 
baricitinib, filgotinib, l estaurtinib, pacritinib).  
7. Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV 
radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or 
intention to have such exposure during the study, which is thought by [CONTACT_501023] 's AD.  
8. Pregnant or lactating, or considering pregnancy during the period of their study 
participation . 
9. History of alcoholism or drug addiction within 1 year before screening or curre nt alcohol 
or drug use that, in the opi[INVESTIGATOR_871], will interfere with the participant 's 
ability to comply with the administration schedule and study assessments.  
10. Current treatment or treatment within 30 days or 5 half -lives (whichever is lon ger) before 
baseline with another investigational medication or current enrollment in another 
investigational drug protocol.  
11. Current treatment or treatment within 30 days or 5 half -lives (whichever is longer) before 
baseline with a  strong CYP3A4 inhibitor . 
12. Removed during Protocol  Amendment 1 . 
13. Known allergy or reaction to any component of the study cream formulation . 
14. In the opi[INVESTIGATOR_500993].  
15. Committed to a mental h ealth institution by [CONTACT_501024].  
16. Employees of the sponsor or investigator or are otherwise dependents of them . 
Incyte Corporation  Page 26 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  5.3. Lifestyle Considerations  
Prolonged exposure to natural or artificial sour ces of UV radiation (including sun lamps, tanning 
booths, etc) is prohibited from [ADDRESS_645271] reconsent (if rescreened ≥ 28 days after the 
initial screening  or ≥ 35 days after the initial screening for those participants on prior 
medications requiring a 4 -week washout period, as described in Section  5.2, Exclusion Criterion 
5b) and be assigned a new participant number.  
5.5. Replacement of Participants  
Participants are not anticipated to be replaced during the study. H owever, as noted in 
Appendix  B, due to the evolving situation of the COVID -19 pandemic, the sponsor may decide 
to recruit additional participants in the study beyond the expected nu mber (eg, if a substantial 
number of participants withdraw early from the study).  
Incyte Corporation  Page 27 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  6. STUDY TREATMENT  
6.1. Study Treatment  Administered  
Table  6 presents  the study treatment information.  
Table  6: Study Treatment Information  
Study T reatment Name:  [CONTACT_501057] F ormulation:  Cream  
Unit Strength : 1.5%  
Route of A dministration:  Topi[INVESTIGATOR_500994]:  BID. A thin film is applied to areas affected by [CONTACT_501025] 1 hour before bedtime . 
Packaging and L abeling:  Ruxolitinib cream will be provided in 60 -g tube s. Each tube will be 
labeled as required per country requirement s. 
Storage:  Ambient (15°C -30°C/59°F -86°F)  
Status of Treatment in 
Participating C ountries:  Approved in the USa; investigationa l in all other countries  
a Opzelura (ruxolitinib) cream . 
Ruxolitinib cream study drug will be supplied in 60 -g tubes and applied topi[INVESTIGATOR_178106] a thin film 
BID (optimally at equal intervals, eg, i deally [ADDRESS_645272] 8 hours between 
applications) to the affected areas in the morning and in the evening, with the evening 
application at least 1 hour before bedtime.  
At the baseline visit, an estimate of the %BSA to be treated will be  used by [CONTACT_501026]. All AD areas identified at the 
baseline  visit should continue to be treated through the end of the CT period (at Week 8), even if 
the area  begins to improve or the AD resolves completely, unless the participant meets any 
criteria for  stoppi[INVESTIGATOR_500995] . 
If there are new areas to be treated, including expansion of existing areas or development of new 
areas, after consultation with the invest igator,  and if there are no safety concerns,  study cream  
should be applied to these areas in addition to the areas identified at the baseline visit (up to a 
maximum total of 20% BSA) for the remainder of the CT period, and the percentage of BSA to 
be treat ed will be recalculated and increased accordingly. This new estimate will be entered into 
the IRT system to calculate the number of tubes of study cream  to be dispensed. Approval to 
treat these additional areas may occur via telephone, although the investi gator, at their discretion, 
may ask the participant to return for an unscheduled visit. This is a close reflection of the clinical 
practice of managing AD in the outpatient setting. During the CT period, participants whose 
additional new areas to be treate d in addition to the areas  identified at the baseline visit exceed 
20% BSA should be discontinued from study cream  and complete the E T assessments.  
During the LTS period (ie, starting at the Week 8 visit ), participants will have study visits at 
Week 12 and  then every 8 weeks until the end of the study (44 weeks total), with the final 
possible application being the evening application on the day before the Week [ADDRESS_645273] confirm appropriate temperature conditions (ruxolitinib cream 
is to be stored between 15°C and 30°C [59°F -86°F]) have been maintained during transit for all 
study cream  received and any discrepancies are reported and resolved before use of the study 
cream . 
Only participants enrolled in the study may receive study cream , and only authorized site staff 
may distribute study cream . The cream will be applied by [CONTACT_501027]/his parent/legal 
guardian.  Immediately after application of study cream , the han ds should be thoroughly washed 
with soap and water , except where there are AD lesions on the hands . Note that the study cream 
is for exclusive use on the skin.  In case of accidental exposure to the eyes or mucous membranes, 
the cream should be immediately removed from that area and necessary supportive measures 
taken.  Refer to the Study Manual for participant instructions for handling of study cream .  
All study cream  must be stored in a secure, environmentally controlled, and monitored (manual 
or automated)  area in accordance with the labeled storage conditions with access limited to the 
investigator and authorized site staff.  Participants should store study cream  at ambient 
temperature conditions.  
The investigator or designee is responsible for study cream  accountability, reconciliation, and 
record maintenance (ie, receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_501028] n at any time by [CONTACT_75478].  The 
investigator or designee must maintain records that document  the following : 
• Delivery of study cream  to the study site.  
• Inventory of study cream  at the site.  
• Participant use of the study cream , including tube counts from each supply dispensed.  
• Return of study cream  to the investigator or designee by [CONTACT_4317].  
The investigational product  must be used only in accordance with the Protocol.  The investigator 
will also maintain records adequately docu menting that the participants were provided the 
specified study cream . These records should include dates, quantities, and any available batch or 
serial numbers or unique code numbers assigned to the investigational product  and study 
participants.  
Complete d accountability records will be archived by [CONTACT_779].  The investigator or designee will 
be expected to collect and retain all used, unused, and partially used containers of study cream  
until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_1142]).  At the conclusion 
of the study, the investigator or designee will oversee destruction  of any remaining study cream 
according to institutional SOPs. If however, local procedures  do not allow on -site destruction, 
shipment of the study cream back to the sponsor is allowed. In this case, the site should (where 
local procedures allow) maintain the study cream supply  until the study monitor inspects the 
accountability records in order to evaluate comp liance and accuracy of accountability by [CONTACT_501029] 30 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  investigative site. At sites where the study cream  is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site SOP.  
Further guidance and information for the final dispo sition of unused study cream  are included in 
the study materials provided to sites.  
6.3. Measures to Minimize Bias:  Randomization and Blinding  
Not applicable .  
6.4. Study Treatment Compliance  
Compliance will be assessed for frequency of application of study cream  by [CONTACT_501030] ' eDiaries.  Participants will also be questioned regarding study cream  application 
technique, missed applications, and use of any additional topi[INVESTIGATOR_500996] -the-counter products.  Com pliance with study cream  will be evaluated by 
[CONTACT_2299] 's adherence to the BID application regimen (evaluation of actual number vs 
prescribed number of applications) and documented by [CONTACT_352966]/designee.  
Qualified cl inical staff will review the eDiary entries for compliance.  Participants will be 
considered compliant with the treatment regimen if they apply at least 80% but no more than 
120% of the prescribed number of applications during participation in the CT period  of the study.  
Participants who are noncompliant during the CT period and LTS period (if on a treatment cycle) 
will be reinstructed by [CONTACT_093] (or designee), and the sponsor should be consulted by [CONTACT_501031].  
Drug accountability will be assessed by [CONTACT_501032] (tube counts and weighing).  At the first clinic visit and subsequent study visits, the amount 
of study cream  to be applied is to be determined by [CONTACT_17832] a tube before and after the 
participant applies a thin film of study cream  to the affected areas.  Participants will be instructed 
to bring all study cream  with them to the study visits in order for site personnel to assess study 
cream  accountability.  
6.5. Dose Modifica tions 
There are no application adjustments/modifications allowed (decrease or increase in study cream  
strength or frequency of application) except for drug interruption or permanent discontinuation if 
needed (eg, for management of an AE).  
Temporary interruption could be due to an AE during the CT or LTS periods or due to clearance 
of the AD lesions during  the LTS period, as described in Section  6.1. 
6.5.1.  Criteria and Procedures for Interruptions of Study Cream  
Safety concerns should be discussed with the med ical monitor immediately upon occurrence or 
awareness to determine whether the participant should continue or discontinue study cream . 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs 
or laboratory abnormalit ies that may have an unclear relationship to study cream . In the event 
that an AE is present only at a specific site of study cream  application, treatment may be 
Incyte Corporation  Page [ADDRESS_645274] ed 
as a dose interruption on the AE eCRF page.  Except in cases of emergency, it is recommended 
that any findings of concern (eg, AE) be confirmed and that the investigator consult with the 
medical monitor before interrupting study cream  applications.  Addit ionally, the investigator must 
obtain approval from the medical monitor before restarting study cream . Participants who 
experience a recurrence of the initial AEs upon restarting the study cream  may need to 
permanently discontinue treatment with the study cream . 
Participants should be closely monitored for the development of signs and symptoms of infection 
during treatment with the study cream  and up to the safety follow -up visit. Study cream  should 
be interrupted if a participant develops a serious infecti on, an opportunistic infection, or sepsis. 
Study cream  application should not be resumed until the infection is controlled.  
Instructions for interruption of study cream –related lab oratory  abnormalities are outlined in 
Table  7. 
Table  7: Guidelines for Interruption and Restarting of Study Cream  Due to 
Laboratory Abnormalities  
AE Related to Study Cream  Action Taken  
Any Grade 3 laboratory abnormality  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results requested.  
• Interrupt study cream , based on clinical judgment in 
consultation with the medical monitor (whenever 
possible), taking into account the relatedness of the AE 
to the study cream  and the participant 's underlying 
condition.   
• Interruption may occur after the initial test result or may 
be del ayed until or unless the repeat test confirms the 
laboratory  abnormality; however, if the repeat test does 
confirm the lab oratory  abnormality, the study cream  
must be interrupted unless the medical monitor approves 
continuation . 
• At the discretion of the in vestigator, after consultation 
with the medical monitor , study cream  application may  
be restarted once the AE has  resolved.  
Any Grade 4 laboratory abnormality  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results requested.  
• Permanently d iscontinue study cream  if laboratory 
abnormalities are confirmed.  Study cream  may also be 
discontinued after the initial lab oratory  abnormality, 
with approval from the medica l monitor.  
Incyte Corporation  Page [ADDRESS_645275] permanently discontinue study cream  if they meet any of the following criteria : 
• Occurrence of an AE that is related to treatment with the study cream  that, in the 
judgment of the investigator or the medical monitor, compromised the participant 's 
ability to continue study -specific procedures or is considered to not be in the 
participant 's best interest.  
• Worsening of AD that requires treatment with a pr ohibited concomitant medication . 
• Any Grade 4 laboratory abnormality  related to the study cream  (see Table  7). 
• Persistent AE requiring a n interruption o f study cream  for more than 2 weeks without 
resolution of the AE.  
See Section  7 for discontinuation procedures.  
6.6. Concomitant Medications  and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF  as 
follows:  
• Non-AD medications and treatments that are taken betwe en [ADDRESS_645276] application of study cream . 
• AD medications and treatments that are taken between [ADDRESS_645277] application of study 
cream should be recorded for SAEs as defined in Section  9.2. Concomitant 
treatments/procedures that are required to manage a participant 's medical condition during the 
study will also be recorded in the eCRF.  The medical mon itor should be contact[CONTACT_112749].  
6.6.1.  Permitted Medications  and Procedures  
The following are permitted during the study:  
• Participants may use bland emollients (except those containing urea, salicylic ac id, or 
lactic acid) such as Eucerin cream.  Participants should continue to use the bland 
emollient/moisturizer in the same manner they did before entering the study and 
throughout the course of the study.  
Note:  Emollients should not be used within 4  hours before and 2 hours after 
application  of study cream . 
Incyte Corporation  Page 33 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  • Bathing during the study should be limited to once daily for no longer than 
15 minutes  and not within 2 hours following study cream  application . During baths, 
tepid (not hot) water and mild cleansing age nts (eg, Basis® bar or Dove®) should be 
used.  (See Section  5.3 for swimming guidance.)  Showers should be limited in time 
with warm water and mild clean sing agents used.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc oxide – or titanium 
oxide –based) with SPF of at least [ADDRESS_645278] 2  hours after study cream  application.  
• Participants may use non sedating, over -the-counter antihistamines.  
6.6.2.  Restricted Medications  and Procedures  
The following are permitted during the study under specified conditions:  
• Short -term use of systemic corticosteroids may be permitted to treat acute AEs 
(eg, asthma) during the  LTS period, and the decision to keep the participant in the 
study (or to permanently discontinue study cream) will be made in consultation with 
the medical monitor.  
• Participants may continue using sedating  antihistaminic drugs as long as their use is 
part of a preexisting and well-established regimen . There are no restrictions for use of 
nonsedating antihistamines.  
• Use of any over -the-counter, nonprescription preparations deemed acceptable by [CONTACT_501033] . 
• Use of any prescription medication (including phytotherapeutic, herbal, or 
plant -derived preparations) is not permitted within 7 days before the baseline visit 
through the safety follow -up visit , unless deemed acceptable by [CONTACT_093].  
• Immunizations with a live -attenuated  vaccine  are not recommended during the CT 
period (first 8 weeks) unless deemed necessary by [CONTACT_093].  
• Allergen immunotherapy (desensitization) that is ongoing at a stable dose at the time 
of study entry may be continued while on study but only at the same dose . 
• Bleach baths are allowed as long as they do not exceed 2 baths per week and their 
frequency remains the same throughout the study.  
• Participants should not take baths or showers within 2 hours  after study cream  
application.  
• Topi[INVESTIGATOR_900] -infectives or other topi[INVESTIGATOR_393582] 4 hours before and 2 hours after application of study cream . 
Incyte Corporation  Page 34 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  6.6.3.  Prohibited Medications  and Procedures  
The followin g are not permitted during the study:   
• Any investigational medication other than the study cream . 
• Topi[INVESTIGATOR_11930], tacrolimus, pi[INVESTIGATOR_031], and PDE4  inhibitors ( eg, Eucrisa).  
• Other topi[INVESTIGATOR_393583] (except bland emollients as noted in Section  6.6.1 ). 
• Treatment known to affect the course of AD.  
• Systemic corticosteroids  (except the example stated in Section  6.6.2 ), methotrexate, 
cyclosporin A, azathioprine and biologic therapi[INVESTIGATOR_014], or other immunosuppressant 
agents.  
• Phototherapy or tanning beds.  
6.7. Treatment After the End of the Study  
There will be no treatment provided after the end of the study . 
Incyte Corporation  Page [ADDRESS_645279]  be discontinued from study treatment for the following reasons:  
• Lack of efficacy response during the LTS period (defined as no change/improvement 
in either %BSA or IGA score when treated continuously for any 8 -week interval 
during the LTS period ). 
• Worsen ing of AD  during either the CT period or the LTS period, to the point where 
the extent of AD to be treated (ie , all areas excluding the scalp) exceeds 20% BSA.  
• The participant becomes pregnant.  
• Consent is withdrawn.  
Note:  Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case , no further data, except data in the 
public domain, may be solicited from or collected on the participant.  Participants may 
choose to discontinue study treatment and remain in the study to be followed for 
safety monitoring.  
• Further participation would be injurious to the participant 's health or well -being, in 
the investigator 's medical judgment.  
• Any AE of unacceptable severity  as noted in Section  6.5.2 . 
• The study is terminated by [CONTACT_456].  
• The study is terminated by [CONTACT_19407], IRB, or IEC.  
A participant  may be discontinued from study treatment as follows:  
• If, after 2 consecutive study visits and reinforcement of study cream  application  
guidance  by [CONTACT_6624], a participant 's drug usage exceeds one 60 -g tube per week , a 
participant who again fails to meet c ompliance benchmarks at a subsequent visit may 
be considered for withdrawal from the study.  The medical monitor should be 
consulted for instruction on handling the participant.  
• If, during the course of the study, a participant is found not to have met elig ibility 
criteria, the medical monitor, in collaboration with the investigator, will determine 
whether the participant should be withdrawn from study treatment.  
• If a participant is noncompliant with study procedures or study cream  application  in 
the investi gator 's opi[INVESTIGATOR_1649], the medical monitor should be consulted for instruct ion on 
handling the participant . 
Incyte Corporation  Page 36 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  7.1.2.  Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the study treatment  prior to the 
Week 52/EOT [ADDRESS_645280] application of 
study cream  and the reason for discontinuation of study cream  will be recorded in the eCR F. 
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for discontinuation  must be documented in the participant 's medical 
record and the primary reason for discontinuation  must be included in the eCRF.  
• The E T visit should be performed  and date recorded  in the eCRF . 
• Participants must be followed for safety until the time of the follow -up visit or until 
study treatment –related AEs resolve, return to baseline, or are deemed irreversible, 
whicheve r is longest . 
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow -up data (safety follow -up), then no additional data collection should occur; however, 
participants will have the option of withdrawing con sent for study treatment but continuing in the 
follow -up period of the study for safety  assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at their own request or may be withdrawn 
at any time at the dis cretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  If a participant 
withdraws from the study, they may request destruction of any samples taken and not tested, and 
the investigator must document this in the site study records.  
Data to be collected at the time of study withdrawal  and follow -up and for any further 
evaluations should conform to the requirements of the ET/EOT visit (see Table  3 [CT period] 
and Table  4 [LTS period] ). 
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if they repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298] . 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_31823] t and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study.  
Incyte Corporation  Page 37 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  • Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant 's last known mailing address 
or local equiva lent methods) . These contact [CONTACT_21457] 's medical record.  
• Should the participant continue to be unreachable, they will be considered to have 
withdrawn from the study . 
8. STUDY ASSESSMENTS AN D PROCEDURES  
See Appendix  B for COVID -19 pandemic –related guidance.  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or their representat ive will explain the nature of the study to the 
participant or their legally authorized representative and answer all questions 
regarding the study.  
− Informed consent must be obtained before any study -related procedures are 
conducted, unless otherwise speci fied by [CONTACT_89191].  
− Informed consent must be obtained using the IRB/IEC -approved version in a 
language that is native and understandable to the participant.  A template will be 
provided by [CONTACT_3552].  The sponsor or its designee must review 
and acknowledge the site -specific changes to the ICF template.  The ICF must 
include a statement that the sponsor or its designee and regulatory authorities have 
direct access to participant records.  
− The ICF must contain all required elements and des cribe the nature, scope, and 
possible consequences of the study in a form understandable to the study 
participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be required  to sign a statement of informed 
consent /assent  that meets the applicable requirements and regulations for the 
countries  in which the study is being conducted as well as the IRB/IEC or study 
center.  
• The participant must be informed that their personal stud y-related data will be used 
by [CONTACT_89192].  The level of disclosure 
must also be explained to the participant.  
• The participant must be informed that their medical records may be examined by 
[CONTACT_501034], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
Incyte Corporation  Page 38 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  • The medical record must include a statement that written informed consent was 
obtained before the partici pant underwent any study -related procedures  and the date 
the written consent was obtained.  The authorized person obtaining the informed 
consent must also sign the ICF /assent . 
• Participants must provide consent to the most current version of the ICF /assent  during 
their participation in the study.  
• A copy of the ICF(s) /assent(s)  must be provided to the participant or the participant 's 
legally authorized representative.  
8.1.2.  Screening Procedures  
Screening is the interval between signing the ICF/assent and the day the  participant is enrolled in 
the study (Day  1). Informed consent (or assent) must be obtained before performing any 
study -specific procedures.  Screening assessments for determination of eligibility may be 
performed over a period of up to 28 days , or up to 3 5 days for participants on prior medications 
requiring a 4 -week washout period,  as described in Section  5.2 (Exclusion Criterion 5b) . 
Assessments that are required to demonstrate eligibility may be performed over the course of 
[ADDRESS_645281] recent available laboratory result s before 
enrollment  will be used to determine eligibility.  Additionally, a participant who fails screening 
may repeat the screening process 1  time if the investigato r believes that there has been a change 
in eligibility status (eg, after recovery from an infection).  The participant is not required to sign 
another ICF if the rescreening occurs within 35 days (screening period) of the previous ICF 
signature [CONTACT_568].  
See Section s 5.[ADDRESS_645282] period and the LTS period as indicated in Table  3 and Table  4, respectively, to 
update the study cream  supply.  The IRT system will also be used during the study visits to 
recalculate the amount of study cream  to be dispensed if the participant 's %BSA of AD lesions to 
be tre ated has increased (during the CT period) or has either increased or decreased (during the 
LTS period).  Additional details are provided in the IRT Manual.  
Incyte Corporation  Page 39 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  8.1.4.  Distribution of Reminder s and eDiaries  
Starting at the Day 1 visit, each participant will use a study cream –specific eDiary in order to 
record use of the study cream . The completed eDiary will b e reviewed during each of the 
participant 's study visits and data will be confirmed by [CONTACT_5984].   
Qualified clinical study  staff will review the participants ' entries for compliance , as outlined in 
Section  6.4. 
Participants will be provided with a reminder starting on Day [ADDRESS_645283] 
been completed.  
8.1.5.  Demography and Medical History  
[IP_ADDRESS].  Demographics a nd General Medical History  
Demographic data and general medical history will be collected at screening by [CONTACT_312356]/age, race, ethnicity, medical and surgical 
history, and current illnesses.  Gener al medical history will include relevant medical or surgical 
treatment within the past 2 years that are considered to be clinically significant by [CONTACT_1275].  Treatment history for AD is covered in Section  [IP_ADDRESS] . 
[IP_ADDRESS].  Disease Characteristics and Treatment History  
An AD -targeted medical and treatment history will be collected at screening . Details regarding 
the participant 's AD, including date of diagnosis and relevant disease characteristics , will be 
recorded.  A medical history of other conditions related to AD will also be collected at this time.  
In addition, information about  topi[INVESTIGATOR_2855],  prescription AD treatment s (eg, name, sta rt/end dates, 
regimen)  used within 12 months prior to screening , and the reason for discontinuation 
(eg, inadequate response, intolerance)  will be collected.  
Also, information about when the use of topi[INVESTIGATOR_2855] , prescription AD treatments  within 12 months 
prior  to screening was not advisable will be collected. An example of when other topi[INVESTIGATOR_500997]/safety risks and/or skin tolerability issues that outweigh the 
potential treatment benefits and are the reason why a topi[INVESTIGATOR_500998].  
Acceptable documentation for the use of  topi[INVESTIGATOR_500999] (within  12 months  prior to screening ) include : 
• Medical records, and/or 
• Communication with the participant 's treating physician , and/or 
• Investigator documentation based on : 
o An interview with the participant or legal  representative ; and/or 
o Review of participant - or legal representative -reported medication history . 
Incyte Corporation  Page 40 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  8.2. Efficacy Assessments  
8.2.1.  Health Economics  
Not applicable.  
8.2.2.  Percent Body Surface Area Affected by [CONTACT_501035] %BSA affected  by [CONTACT_501036] (see Table  3 
[CT period] and Table  4 [LTS period] ). Body surface area assessment will be approximated to 
the nearest 0.1% using the handprint ( palmar) method as a guide.  The approximate size of the 
participant 's entire palmar surface (ie, the palm plus 5 digits, with fingers tucked together and 
thumb tucked to the side) should be considered as 1% BSA, and the approximate size of the 
participant 's thumb should be considered as 0.1% BSA.   
Participants must have BSA involvement (excluding the scalp) of 3% to 20% at the screening 
and baseline visits to enroll in the study; they must  have 0% to 20% BSA involvement at Week 8 
(baseline for the LTS period) to enter the LTS period.  
During the LTS period, including Week 8 (baseline for the LTS period), %BSA will be 
evaluated by [CONTACT_501037] (re)enter an observation/no treatment cycle . 
8.2.3.  Investigator 's Global Assessment  
Investigator 's Global Assessment is an overall eczema  severity rating on a 0 to 4 scale that will 
be assessed for the whole body (total IGA) and for the face only (facial IGA) during site visits  as 
outlined in the SoA (see Table  3 [CT period] and  Table  4 [LTS period] ). The area "Face " is 
defined as including the area on the forehead to the original hairline, on the cheek to the jawline 
vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face " 
will not include the surface area of the lips, scalp , ears, or neck but will include the nose and 
eyelids.  The severity strata for the IGA are shown in  Table  8. 
Table  8: Investigator 's Global Assessment  
Grade  Severity  Status  
0 Clear  No erythema or induration/papulation, no oozing/crusting; there may be 
minor residual discoloration  
[ADDRESS_645284] no 
induration/papulation, and no oozing/crusting  
2 Mild  There may be faint pi[INVESTIGATOR_80169], with mild induration/papulation and no 
oozing/crusting  
3 Moderate  There may be pi[INVESTIGATOR_8745] -red erythema with moderate induration/papulation and 
there may be some oozing/crust ing 
4 Severe  There may be deep or bright red erythema with severe induration/papulation 
and with oozing/crusting  
Source:  FDA [ADDRESS_645285] a total IGA score of 2 or 3 at the screening and baseline visits to enroll in 
the study; there is no limitation for  total or facial IGA score at Week 8 ( baseline for the LTS 
period) to enter the LTS period.  
During the LTS period, including Week 8 (baseline for the LTS period), total IGA will be 
evaluated by [CONTACT_501038] (re)enter an observation/no treatment cycle.  If the total IGA score is ≥  1, the 
participant will start or continue active treatment with ruxolitinib cream 1.5% BID.  If the total 
IGA score is 0 (clear), the participant will (re)enter an observation/no treatment cycle . 
 
 
 
8.2.4.  Itch N umerical Rating Scale 
The Itch NRS is a daily participant -reported measure (24 -hour recall) of the worst level of itch 
intensity  (Pruritus Resources ). Participants will be asked to rate the itch severity of their AD by 
[CONTACT_20683] a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst 
level of itching in the past 24 hours as outlined in the SoA ( see Table  3 [CT period] and  Table  4 
[LTS period] ). Participants will be issued a n eDiary in which to record itch severity.  The 
participants will be instructed to complete the eDiary each night beginning on the day of 
screening through the last day of  the LTS period.  Detailed directions for the administration of a n 
eDiary will be provided in the  Study Manual . 
8.2.5.  Eczema Area and Severity Index  
Atopic dermatitis will be assessed as outlined in the SoA ( see Table  3 [CT period] and  Table  4 
[LTS period] ) using the EASI scoring system  (refer to the Study Manual) , which is a validated 
scoring system that grades the physical signs of AD to provide a measure of AD severity 
(ranging from 0 to 72 ; Hanifin et al 2001 ). The EASI scoring system examines 4 regions of the 
body (head/ne ck, upper limbs, trunk, and lower limbs) and weights them.  Each of the 4 body 
regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations 
(Ex), and lichenification (L) for an average degree of severity of each sign in eac h region.  
The severity strata for the EASI are as follows:  0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 
7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; and 50.1 to 72.0 = very severe  
(Leshem et al 2015 ). 
8.3. Safety Assessments  
Planned timepoints for all safety assessments are provided in the SoA ( see Table  3 [CT period] 
and Table  4 [LTS period]).  
See Section  6.[ADDRESS_645286] application  of study  drug. Adverse events for enrolled participants that 

Incyte Corporation  Page 42 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  begin or worsen after informed consent /assent  should be recorded on the Adverse Events Form 
in the eCRF  regardless of the assumption of a causal relationship with the study cream . 
Conditions that were already present at the time of informed consent /assent should be recorded 
on the Medical History Form in the eCRF . Adverse events (including laboratory abnormalities 
that constitute AEs) should be described using a diagnosis whenever possible rather than by 
[CONTACT_147108].  
Advers e events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative) . The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following  up on AEs that are serious, 
considered related to the study cream /procedures, or caused the participant to discontinue the 
study cream . Care will be taken not to introduce  bias when detecting AEs and/or SAEs . 
Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feeling? ", is the preferred method to inquire about AE  occurrences . Adverse events may also be 
detected when they are volunteered by  [CONTACT_501039] s, laboratory test s, or other assessments . The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be reported to the sponsor or designee within 24 hours . The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available.  
After  the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts . All SAEs  and AEs will be followed until resolution, stabilization, 
the event is otherwise explained, or the participant is lost t o follow -up (as defined in 
Section  7.3). 
8.3.2.  Physical Examinations  
During the study, participants will be assessed by [CONTACT_501040] . Physical examinations will be conducted at the 
timepoints listed in the SoA ( see Table  3 [CT period] and Table  4 [LTS period]) . 
[IP_ADDRESS].  Comprehensive Physical Examination  
At the screeni ng visit and Week 52/EOT2 or ET visit , a comprehensive physical examination 
should be conducted.  The comprehensive physical examination will include assessment(s) of the 
following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lu ngs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes; as well as a brief 
neurological examination.  
[IP_ADDRESS].  Targeted Physical Examination  
At the visits  indicated in the SoA (see Table  3 [CT period] and Table  4 [LTS period]) , a targeted 
physical examination will be a symptom -directed evaluation (ie, conducted only if indicated by 
[CONTACT_23805], AEs, or other findings ); clinically significant abnormalities  (in the investigator 's 
judgment) are to be reported as AEs and documented on the Adverse Events Form in the  eCRF.  
Incyte Corporation  Page 43 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  8.3.3.  Vital Signs , Height, and Weight  
Vital signs, height, and weight will be measured as outlined in the SoA ( see Table  3 [CT period] 
and Table  4 [LTS period]) . 
Vital sign measurements (to be taken before blood /saliva  collection for laboratory tests) include 
blood pressure, pulse, respi[INVESTIGATOR_697], and body temperature . Blood pressure a nd pulse will be 
taken with the participant  in the sitting position after [ADDRESS_645287] application of study cream  constitute an AE if they are considered 
clinically meaningful, induce clinical si gns or symptoms, or require concomitant therapy.  
Height and weight will be assessed at the baseline , Week 8/ EOT1/ ET, Week 28, and 
Week  52/EOT 2/ET visits . Height will be measured using a stadiometer.  The stadiometer should 
be calibrated , and a wall-mounted  one is recommended.  Participants should be measured without 
socks and [ADDRESS_645288] 0.1 cm. The average of the 3 height 
measurements of individual participants should be recorded in the eCRF.  
8.3.4.  Electrocardiograms  
A single 12 -lead ECG w ill be obtained at screening (12 -lead ECG performed within 2 months 
before baseline is acceptable) using an ECG machine that automatically calculates the heart rate 
and measures PR, QRS, QT, and QTc intervals. All [ADDRESS_645289].  
The decision to include or exclude a participant or withdraw a participant from the study cream  
based on an ECG flagged as "Abnormal, Clinically Significant " is the responsibility  of the 
investigator, in consultation with the sponsor 's medical monitor, as appropriate. Clinically 
notable abnormalities that are considered clinically significant in the judgment of the investigator 
are to be reported as AEs.  
8.3.5.  Laboratory Assessments  
See Table  [ADDRESS_645290] of clinical laboratory tests to be performed and the SoA (see Table  3 [CT 
period] and Table  4 [LTS period])  for the timing and frequency . A central laboratory will 
perform all clinical laboratory assessments for safety (ie, blood chemistries and hematology 
assessmen ts) and will store t he samples for PK analysis . Additional testing may be required by 
[CONTACT_89202] . All Protocol -required laboratory assessments must be 
conducted in accordance with the Laboratory Manual and  the SoA (see Table  3 [CT period] and 
Table  4 [LTS period]) . Information regarding collection , processing, and shippi[INVESTIGATOR_501000].  
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_501041] 's condition . All laboratory tests with values considered clinically significantly 
abnormal during participation in the study or within  [ADDRESS_645291] application  of study 
cream  should be repe ated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_10982].  
If screening laboratory assessments are performed less than  or equal to 2 weeks  before Day 1, 
then the Day 1  serum chemistry and hematology assessments do not need to be performed . 
Incyte Corporation  Page 44 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  See Section  9.1 for information regarding laboratory abnormalities that sho uld be recorded as an 
AE in the eCRF . 
Table  9: Required Laboratory Analytes  
Blood Chemistries  Hematology  Serology  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Blood urea nitrogen or urea  
Calcium  
Chloride  
Creatine kinase  
Creatinine  
Glucose  
Lactate dehydrogenase  
Phosphate  
Potassium  
Sodium  
Total bilirubin  
Direct bilirubin (if total bilirubin is 
elevated above ULN)  Complete blood count, including:  
• Hemoglobin  
• Hematocrit  
• Mean corpuscular volume  
• MPV  
• Platelet count  
• Red blood cell  count  
• White blood cell  count  
 
Differential count (absolute and %), 
including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  HIV antibody  
 
 
 
 
 
 
Pregnancy Testing  
WOCBP  will have a serum test at 
screening and a urine test at all 
other visits.  
A positive urine test must  be 
confirmed by a serum test.  
Note:  Additional tests may be required, as agreed upon by [CONTACT_86206] , based on emerging safety data or to rule 
out a diagnosis.  
[IP_ADDRESS].  Pregnancy Testing  
A serum pregnancy  test will be required for all women of childbearing potential during 
screening . Urine pregnancy tests will be performed locally as outlined in  the SoA (see Table  3 
[CT period] and Table  4 [LTS period]) , as medically indicated (eg, in case of loss of menstrual 
cycle, when pregnancy is suspected), or per country -specific requirement (no te that 
country -required urine pregnancy testing will be outlined and communicated to investigational 
sites under separate cover) . If a urine pregnancy test is positive, the results must  be confirmed 
with a serum pregnancy t est. 
If the serum pregnancy test is negative after a urine test was positive, t he investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant 's best 
interest to resume study cream  and continue parti cipation in the study.  
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.7 for reporting 
requirements.  
[IP_ADDRESS].  Serology  
An HIV antibody assessment  will be performed at the screening visit to rule out HIV infection . 
Generally, HIV tests should be performed early in the screening process due to the length of time 
needed to obtain the results . Additional tests may be performed if clinically indicated.  
Incyte Corporation  Page 45 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  8.4. Pharmacokinetic Assessments  
Pharmacokinetic blood and saliva samples will be collec ted from all participants  at the visits and 
collection times shown in the SoA ( see Table  3 [CT period] and Table  4 [LTS period] ) and  as 
noted in  Table  10. 
The exact date and time of the PK blood and saliva sampling and the date and time of the last 
application of study cream  preceding the blood or saliva sample (if applicable) will be recorded  
in the eCRF.  
Instructions for sample preparation and shippi[INVESTIGATOR_352884]. 
Participants will receive reminders in advance of the study visit providing instruction s to hold the 
application of study cream  on the day of the visi t and to record the time of the prior application 
of study cream . 
Blood samples for PK must be drawn from an area that has not been treated with study cream, or  
if that is not possible,  the participant must not apply study cream from the previous applicati on 
of study cream on the immediate body area where blood is to be drawn (ie , for site visits in the 
morning, this means the application on the evening before [second dose of that day]; for site 
visits in the afternoon this means the application on the morn ing of the same day [first dose of 
that day]).   
If blood is drawn from an area that has been treated with study cream , the site personnel must 
document the missed application at the location of the blood draw in the eCRF. After the PK 
blood or saliva sampl e is collected , participants will apply ruxolitinib 1.5% cream.  
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte 's designee.  
Table  10: Pharmacokinetic Blood and Saliva Sample Timing  
Study Visit  Timing of Sample  
CT period  
 
 
 
• Week 2  
• Week 4  
• Week 8/E OT1 or ET  Samples will be collected at any time prior to study cream application during study 
visits, but must be at least 4 hours after the previous application of study cream  
and after assessment of vital signs during the visit:  
• Blood and saliva samples  
• Blood and saliva samples  
• Saliva sample only  
LTS period : Weeks 12, 20, 
28, 36, 44 , and 52/EOT2   Saliva s amples will be collected at any time prior to study cream application 
during study visits, but must be at least 4 hours after the previous application of 
study cream and after assessment of vital signs  during the visit.  No blood samples 
will be collected during the LTS period.  
8.5. Pharmacodynamic and Translational Assessments  
Not applicable.  
Incyte Corporation  Page 46 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  8.6. Unscheduled Visits  
Unscheduled study visits may occur at any time medically warranted, including when 
participants develop new areas of AD  (see Section  6.1). Any assessments performed at those 
visits should be recorded in the eCRF.  
8.7. End of Treatment  and/or Early Termination  
The end of treatment for the CT period (EOT1) coincides with the Week 8 visit.  At that time, if 
the participant continues into the LTS period, then the Week 8/E OT1 visit should be conducted. 
However, if the participant does not continue into the LTS period, the ET evaluations should be 
conducted  instead . For participant s who  permanently discontinue study cream  prior to  the 
Week  8/EOT1  visit, the ET visit  and evaluations  should be conducted.  If the ET visit coincides 
with a regular study visit, then the respective ET evaluations will supersede those of that 
scheduled visit, an d the data should be entered in the ET page in the eCRF.  If the decision to 
permanently discontinue study cream  does not coincide with a regular visit, reasonable efforts 
should be made to have the participant return to the site to have the ET procedures c ompleted . 
The end of treatment for the LTS period, and hence also the whole study (EOT2),  coincides with 
the Wee k 52 visit. A participant who completes the Week 52/EOT [ADDRESS_645292] reached the 
end of treatment with study cream . For participant s who  permanently discontinue study cream  
during the LTS period and prior to the Week  52/EOT [ADDRESS_645293] a safety follow -up visit 30 -37 days following the end of treatment 
(Week  52/EOT 2 or ET) to evaluate safety and disease control parameters . One exception to this 
would b e for participants in the LTS period who have been in an observation/no treatment cycle  
with a  total IGA score of  0 (clear)  from Week 48 or earlier until Week 52; for such participants , 
the Week 52/EOT2 visit will also count as  the safety follow -up visit. 
Adverse events and SAEs must be followed  up until 1) at least [ADDRESS_645294] application 
of study cream  or 2) until toxicities resolve, return to baseline, or are deemed irreversible, 
whichever is longer.  Reasonable efforts should be made to have the participant return for the 
follow -up visit and report any AEs that may occur during this period . 
Incyte Corporation  Page 47 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  9. ADVERSE EVENTS:  DEFINITIONS AND PROC EDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of A dverse Event 
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not it is considered drug -related.  
• An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory 
finding), symptom, or disease (n ew or exacerbated) temporally associated with the use of study 
cream . 
Additional Guidance for Events Meeting the Adverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from 
baseline, considered cl inically significant in the medical and scientific judgment of the investigator 
(ie, not related to progression of underlying disease) are to be reported as an AE.  
• Abnormal laboratory test results are to be reported as an AE if they are considered clinical ly 
meaningful, induce clinical signs or symptoms, require concomitant therapy, or require changes in 
study cream . Whenever possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in 
the eCRF rather than the abnormal laboratory test result ( eg, low hemoglobin, platelet count 
decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition/disease, including either an increase 
in the frequency and/or intensity of the condition, is to be reported as an AE.  
• New conditions detected or  diagnosed after the start of study cream  application  are to be reported as 
an AE.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction are to be reported as 
an AE.  
• Signs and/or symptoms from dosing errors of a study cream  (eg, ov erdose) or a concomitant 
medication are to be reported as an AE.  
• "Lack of efficacy, " or "failure of expected pharmacological action " will not be reported as an AE or 
SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, symptoms, 
and/or clinical sequelae resulting from lack of efficacy will be reported as an AE or SAE if they 
fulfill the definition of an AE or SAE.  
• A condition that leads to a medical or surgical procedure (eg, endoscopy, appendectomy)  will be 
reported as an AE if it occurs after obtaining informed consent /assent . If the condition is present 
before entering the study, then it should be captured as medical history.  
• Pre-existing diseases or conditions with expected fluctuations in signs o r symptoms should be 
reported as an AE only if the investigator judges the fluctuation to have worsened more than 
expected during study participation.  
Incyte Corporation  Page 48 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  9.2. Definition of S erious Adverse Event 
If an event is not an AE per the definition above, then it cannot be  an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due 
to progression of disease).  
A serious adverse event is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term "life-threatening " in the definition of "serious " refers to an adverse drug experience that 
places the participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience as it occur s. This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death . 
c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_319850] (involving at least an 
overnight stay) at the hospi[INVESTIGATOR_501001]/or treatment that would 
not have been appropriate in the physician 's office or outpatient setting.  Complications that occur 
during hospi[INVESTIGATOR_209418].  If a complication prolongs hospi[INVESTIGATOR_40030], the event is serious.  When in doubt as to whether hospi[INVESTIGATOR_51956], 
the AE should be considered serious.  
Hospi[INVESTIGATOR_501002] (eg, stent replacement, hip surgery) is not 
considered an SAE.  
Hospi[INVESTIGATOR_501003] 
(ie, elective procedures or routine medical visits) is not considered an SAE.  
d. Results in persistent or significant disability/incapacity  
• The term "disability " means a substantial disruption of a person 's ability to conduct normal life 
functions.  This definition is not intended to include experiences of relati vely minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental 
trauma (eg,  sprained ankle), that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is an important medical event  
An important medical event is an event that may not result in death, be immediately life -threatening, or 
require hospi[INVESTIGATOR_49200], based on appropriate me dical judgment, 
the event may jeopardize the participant and may require medical or surgical intervention to prevent 
one of the outcomes listed in the above definition.  Examples of such events include new invasive or 
malignant cancers ; intensive treatment in an emergency department or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059] ; or development of 
drug dependency or drug abuse . Secondary malignancies should always be considered SAEs . 
Incyte Corporation  Page 49 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  9.3. Recording an d Follow -Up of A dverse Events and/or S erious Adverse 
Events 
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event s Form in the eCRF.  All AEs/SAEs should be reported for enrolled participants , but 
only SAEs need to be reported for screen failure participants.  For enrolled participants, c onditions 
that were present at the time informed consent was given should be recorded on the Medical Histo ry 
Form in the eCRF.  For detailed information , refer to the eCRF guidelines . 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related t o the event.  
• The investigator (or designee ) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914] 's medical records 
in lieu of completing the Adverse Event s Form in th e eCRF.  
• There may be rare instances when copi[INVESTIGATOR_63475].  In this 
case, all participant identifiers, with the exception of the participant number, will be redacted by [CONTACT_312366][INVESTIGATOR_501004] . These records can be submitted to 
Incyte Pharmacovigilance by [CONTACT_6968]/fax per  the contact [CONTACT_501042].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each sign or symptom 
should be report ed as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine the following:  
• The severity grade (CTCAE v5.0 Grade 1 to 5).  See below for further instructions on the assessment 
of intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study cream : suspected 
(yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at the final safety follow -up visit.  
• The action taken with regard to study cream  as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousnes s, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:  If an AE is treated with a concomitant medication or 
nondrug therapy, this action should be recorded on the Adverse Event s Form and the treatment 
should be specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures and 
Non-Drug Therapy).  
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5.  If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the 
grade of severity.  
Incyte Corporation  Page 50 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment 
not indicated.  
• Grade 2:  Moderate; minimal, local, or n oninvasive treatment indicated; limiting age -appropriate 
activities of daily living.  
• Grade 3:  Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of daily living.  
• Grade 4:  Life-threatening consequences; urgent treatment indicated.  
• Grade 5:  Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study cream  and each occurrence of 
each AE/SAE.  
• A "reasonable possibility " of a relationship conveys that there are medical facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the p ossibility of a relationship.  
• The investigator will also consult the RSI in the IB in making their assessment.  
• Alternative causes, such as underlying or concurrent disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study cream  application , will be 
considered and investigated.  
• For each AE/SAE, the investigat or must  document in the medical notes that they have  reviewed the 
AE/SAE and have provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal 
informa tion to include in the initial report.  However, the causality assessment is one of the criteria 
used when determining regulatory reporting requirements.  Therefore, it is very important that 
the investigator always make an assessment of causality based on the available information 
for every event before the initial transmission of the SAE.  
− The investigator may change their opi[INVESTIGATOR_9242] -up information and 
submit the update d causality assessment.  
Follow -Up of Adverse Event s and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_89207]/or causality of the AE or SAE as fully as possible.  This may include additional laboratory tests 
or investigations, histopathological examinations, or consultation with other health care 
professionals.  
• Once an AE is detected, it should be followed in the Adverse Events Form in the eCRF until it has 
resolved or until it is judged to be permanent; assessment should be made at each visit (or more 
frequently if necessary) of any changes in severity, the suspected relationship to the study cream , the 
interventions required to treat the e vent, and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg, between visits), each 
change in severity will be reported as a separate AE . 
Incyte Corporation  Page 51 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  • If a participant dies during participation in the study or during a recognized follo w-up period, the 
investigator will provide the sponsor with a copy of any postmortem findings , including 
histopathology.  
• Updated SAE information will be recorded in the originally completed eCRF and reported to Incyte 
Pharmacovigilance until resolution, s tabilization, the event is otherwise explained, or the participant 
is lost to follow -up. 
• Any updated SAE data (including SAEs being downgraded to nonserious) will be submitted to the 
sponsor (or designee) within 24  hours of receipt of the information.  
9.4. Reporting of S erious Adverse Events 
Regardless of suspected causality (eg, relationship to study cream  or study procedure[s]), all 
SAEs occurring after the participant has signed the ICF /assent  through the last safety visit or at 
least [ADDRESS_645295] be reported 
to the sponsor (or designee) immediately, without undue delay but not later than  within 24 hours  
of obtaining knowledge  of its occurrence unless otherwise specified by [CONTACT_89191].  The 
investigator will submit any updated SAE data to the sponsor (or designee) immediately, without 
undue delay but not later than within 24 hours of it being available.  
Investigators are not obligated to actively seek SAE information after conclusion of study 
participation (ie, after the safety follow -up visit or [ADDRESS_645296] application  of study 
cream , whichever occurs later) . If the investigator learns of any SAE, including death, at any 
time after a participant has been discharged from the st udy, and they consider the event to be 
reasonably related to the study cream  or study participation , then the investigator must notify the 
sponsor (or designee) within 24 hours of becoming aware of the event.   
After the initial AE/SAE report, the investiga tor is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs  will be followed until resolution, stabilization, the event 
is otherwise explained,  or the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by [CONTACT_501043] a study 
cream  under clinical investigation are met.  
If the SAE is not documented in the RSI of the IB for the study cream  (new occurrence) and is 
thought to be related to the study cream , the sponsor or its designee may urgently require further 
information from the investigator for expedited reporting to health authorities.  The sponsor or its 
designee may need to issue an Investigator Notification to inform all investigators involved in 
any study with the same drug that this SAE has been reported.  Suspected unexpected serious 
adverse reactions will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per nationa l regulatory requirements 
in participating countries.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study cream  under clinical investigation.  The sponsor 
will comply  with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC , and investigators.  
Incyte Corporation  Page [ADDRESS_645297] be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) f rom the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC , if appropriate , according to local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs is collected and recorded on the Adverse Event s Form in  the eCRF.  
• The investigator must report within 24 hours of learning of its occurrence any SAE via the EDC 
system (primary method) or by [CONTACT_312369] (only 
if the EDC system is not available ). The contact [CONTACT_501044]/fax is listed in the Study Reference Manual or as per the Incyte Reference Guide for 
Completing the Serious Adverse Event Report Form.  
• In circumstances where the EDC system is not accessible for reporting SAE in formation (initial 
and/or follow -up SAE information) to the sponsor within [ADDRESS_645298] be kept at the study site (refer to the Incyte Reference 
Guide for Completin g the Serious Adverse Event Report Form or Study Reference Manual for details 
and for the email address or fax number).  
• Follow -up information is also recorded in the eCRF and transmitted to Incyte Pharmacovigilance via 
the EDC system.  The follow -up report should include information that was not provided previously, 
such as the outcome of the event, treatment provided, action taken with study cream  because of the 
SAE (eg, dose reduced, interrupted, or discontinued ), or participant dispos ition (eg, continued or 
withdrew from study participation).  Each recurrence, complication, or progression of the original 
event should be reported as follow -up to that event, regardless of when it occurs.  
9.5. Events of Clinical Interest  
Not applicable.  
9.6. Emerge ncy Unblinding of Treatment Assignment  
Not applicable.  
9.7. Pregnancy  
Pregnancy, in and of itself, is not regarded as an AE unless there is suspi[INVESTIGATOR_501005] a contraceptive medication or method.  When 
a pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
cream , the following procedures should be followed in order to ensure safety:  
• The study cream  must be discontinued immediately (female participants only).  
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Incyte Corporation  Page 53 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Data on fetal outcome are collected for regulatory reporting and drug safety evaluation s. 
Follow -up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by f ollowing until the first 
well-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211].  Pregnancy follow -up information should be 
recorded on the same form and should includ e an assessment of the possible causal relationship 
to the sponsor 's study cream  to any pregnancy outcome, as well as follow -up to the first 
well-baby [CONTACT_89212], whichever is later.  Refer to the 
Incyte Reference G uide for Completing the Clinical Trial Pregnancy Form .  
Any SAE occurring during the pregnancy of a study participant must be recorded and 
reported as described in Section  9.4. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4. If an abnormal pregnancy outcome is reported in a 
study participant 's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form.  
9.8. Warnings and Precautions  
Special warnings or precautions for the study cream , derived from safety information collected 
by [CONTACT_3552], are presented in the IB. Additional safety information collected 
between IB updates will be communicated in the form of Investigator Notifications.  Any 
important new safety information should be discussed with the participant during the study as 
necessary.  If new significant risks are identified, they will be added to th e ICF /assent . 
9.9. Product Complaints  
The sponsor collects product complaints on study drugs and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate 
process and product improvements.  
All product complaints associated with material packaged, labeled, and released by [CONTACT_319862].  All product complaints associated with other 
study material will be reported directly to the respe ctive manufacturer.  
The investigator or their designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_501045]. Any AE associated with a product 
complaint should be recorded as described in Section  9.3. 
If the investigator is asked to return the product for investigation, they will return a copy of the 
product complaint communication with the product.  
9.10. Treatment of Excessive Use  
There has been no clinical experience with overdose resulting from excessive u se of ruxolitinib 
cream.  Treatment of excessive use should consist of general supportive measures.  
Incyte Corporation  Page 54 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  10. STATISTICS  
10.1. Sample Size Determination  
Approximately 100 participants will be enrolled.  The study is not powered for statistical 
comparison but instead is based on the evaluation of safety. This sample size will provide > 99% 
chance of detecting at least [ADDRESS_645299] if the underlying AE rate is 5% , and therefore it is 
anticipated that sufficient data for safety investigation will be  permitted. As this is an  open -label 
study, all participants will be treated with ruxolitinib 1.5% cream.  
10.2. Populations for Analyses  
The populations for analysis are provided in Table  11. 
Table  11: Populations for Analysis  
Population  Description  
FAS The FAS will include  all participants enrolled in the study who applied  study 
cream  at least once.  The FAS will be used for the summary of demographics, 
baseline characteristics, participant disposition, and all analyses of efficacy and 
safety data.  
PK/hematology 
lab evaluable  The PK evaluable population will include all participants  who applied  study  cream  
at least once  and provided at least 1  postbaseline  PK sample (1 PK measurement).  
The hematology  lab evaluable population will include all participants  who applied  
study cream  at least on ce, provided the baseline hematology blood sample, and at 
least 1 postbaseline hematology blood sample (1 hematology  measurement).  
The PK/hematology  lab evaluable population will include all participants who are 
both PK  evaluable and hematology  lab evaluable.  
10.3. Level of Significance  
This is a safety study. No formal hypotheses will be tested; all ef ficacy analyses are exploratory . 
10.4. Statistical Analyses  
10.4.1.  Primary Analysis  
A TEAE is any AE either reported for the first time or worsening of a pre -existing event after 
first application of study cream  and up to [ADDRESS_645300] a relationship to study cream  will be 
considered to be tr eatment -related AEs.  If the investigator does not specify the relationship of the 
AE to study cream , then the AE will be considered treatment -related.  The incidence of TEAEs, 
treatment -related TEAEs , serious TEAEs, Grade 3 or higher  TEAEs, and TE AEs leadin g to 
Incyte Corporation  Page 55 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  study cream  interruption or study discontinuation will also be tabulated. A summary of primary 
endpoint analyses is provided in Table  12.  
Table  12: Summary of Primary Endpoint Analyses  
Endpoint  Population  Treatment  Population -Level 
Summary Metric  
Incidence of TEAEs, 
treatment -related TEAEs , 
serious TEAEs, Grade 3 or 
higher  TEAEs FAS Ruxolitinib 1.5%  BID cream  Rate of  TEAEs  
Incidence of TE AEs leading to 
study cream  interruption or 
study discontinuation  FAS Ruxolitinib 1.5%  BID cream  Rate of  TEAEs  
Incidence of TEAEs 
summarized by [CONTACT_501046] 1.5%  BID cream  Rates of TEAEs  
10.4.2.  Secondary Analys es 
[IP_ADDRESS].  Clinical Laboratory Tests  
The clinical laboratory data will be analyzed using summary statistics.   
Laboratory test values outside the normal range will be assessed for severity based on the normal 
ranges for the clinical reference laboratory.  The incidence  of abnormal laboratory values and 
shift tables relative to baseline will be tabulated.  In addition, distributions of key laboratory 
parameters may be plotted over time; these values will also be classified into CTCAE toxicity 
grades and tabulated.   
[IP_ADDRESS].  Vital Signs  
Descriptive statistics and mean change from baseline will be determined for vital signs (blood 
pressure, pulse, respi[INVESTIGATOR_697], and body temperature), height , and weight at each assessment 
time.  Vital sign results will be reviewed for clinically no table abnormalities.  
10.4.3.  Pharmacokinetic Analyses  
Descriptive analysis of PK concentration data will be performed by [CONTACT_273424] (plasma and saliva), 
study period, and/or visit, using summary statistics such as, but not limited to, number of 
observations, mean, STD, minimum, median, maximum, geometric mean, geometric coefficient 
of variation, and/or empi[INVESTIGATOR_501006].   
Additional summaries may also be generated by [CONTACT_501047], age, 
%BSA treated, and/or disease s everity indices at baseline, as deemed appropriate.  
Table 13 summarizes all secondary endpoint analyses.  
Incyte Corporation  Page 56 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table 13: Summary of Secondary Endpoint Analyses  
Endpoint  Population  Treatment  Population -Level 
Summary Metric  
Change from baseline 
in vital signs  FAS Ruxolitinib 1.5% BID cream  Descriptive statistics and  
mean change from baseline  
Change from baseline 
in laboratory  values  FAS Ruxolitinib 1.5% BID cream  Descriptive statistics and  
mean change from baseline  
Height  FAS Ruxolitinib 1.5% BID cream  Descriptive statistics  
Weight  FAS Ruxolitinib 1.5% BID cream  Descriptive statistics  
PK concentration  PK evaluable  Ruxolitinib 1.5%  BID cream  Descriptive statistics  
10.4.4.  Exploratory Efficacy Analyses  
 
 
 
  
10.4.5.  Exploratory Analysis of Relationship Between Hematology Lab oratory  Results 
and Trough Ruxolitinib Concentrations  
Exploratory descriptive and/or graphical analys es, as deemed appropriate, will be performed on 
the relationships between clinical lab oratory  test results of select hematology parameters  such as 
platelet count, MPV, hemoglobin , and neutrophil count and the trough ruxolitinib concentration 
by [CONTACT_765].  
Graphical analys es will include line plots of  the mean ± STD values of  the lab oratory  test results 
(the measured value, the change from the baseline, and/or the percent change from the baseline) 
by [CONTACT_501048] (or other ways of 
discretization)  as deemed appropriate.   
The distribution of ruxolitinib concentrations  versus the incidences  and/or grade of severity  of 
clinical lab oratory  CTC AE abnormalities in these hematology endpoints will be explored by [CONTACT_501049] -whisker plots or other type s of visualization, as deemed appropriate.  
Additional groupi[INVESTIGATOR_501007] -level characteristics such as age, %BSA, 
and/or IGA, may also be attempted  in these analyses, as deemed appropriate .  
A summary of all exploratory  endpoint  analyses  is provided in Table  14. 

Incyte Corporation  Page 57 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Table  14: Summary of Exploratory Endpoint Analyses  
10.5. Interim Analysis  
No formal interim analysis is planned in this study . 

Incyte Corporation  Page 58 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol Amendments , ICF /assent , IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC and health autho rities before the study is 
initiated.  
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_89222], the 
policies and procedures established by [CONTACT_1201]/IEC, and institutional requirements.  
• Any amendments to the Protocol will require  approval from  both health a uthorities 
and the IRB/IEC before implementation of changes made to the study design, except 
for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the follo wing:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC.  
− Notifying the IRB/IEC of SAEs or other significant safety find ings as required by 
[CONTACT_1744]/IEC procedures.  
− Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -specific regulations.  
• Adhering to the Protocol as de scribed in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is responsible fo r enrolling participants who have met the 
specified eligibility criteria.  
• Retaining records in accordance with all local, national, and regulatory laws but for a 
minimum period of at least [ADDRESS_645301] article for 
investigation to ensure the availability of study documentation should it become 
necess ary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated with the study during the 
retention period without receiving approval from the sponsor.  The investigator 
must notify the sponsor or its designee in the event of accidental loss or 
destruction of any study records.  If the investigator leaves the institution where 
the study was conducted, the sponsor or its designee must be contact[CONTACT_501050].  
Incyte Corporation  Page 59 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  − All eCRF da ta entered by [CONTACT_779] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations.  
The sponsor will retain the ori ginal eCRF data and audit trail.  
11.1.1.  Identification of the Coordinating Principal Investigator  
A coordinating principal investigator [INVESTIGATOR_501008].  As part of their responsibilities, the coordinating principal inv estigator will review the 
final CSR.  Agreement with the final CSR will be documented by [CONTACT_312374] . 
11.2. Data Management  
Data management will be performed in a validated EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF.  The study monitor will reference the Monitoring Plan in order t o ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan 's requirements.  Other data outside the EDC system required in the study conduct of 
the Protocol , such as documents or res ults transmitted to the sponsor via a central laboratory or 
specialized technical vendors and as designated by [CONTACT_456], will have their own data flow 
management plans, study charters, or biomarker plans, as applicable.  
The sponsor (or designee) will be  responsible for  the following : 
• Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors perform ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_50484], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved Protocol and any other study agreements, ICH  GCP, and all applicable 
regulatory requirements.  
• Managing and reconciling the data generated and/or collected , including documents 
and results such as laboratory or imaging data analyzed centrally by a designated 
vendor of the sponsor.  
The investigator wi ll be responsible for  the following : 
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the delivery of, all other results, documents, data, know -how, 
or formulas relating to the study to t he sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data, biomarker data, photographs, diary data) 
or as otherwise speci fied in the Protocol.  
Incyte Corporation  Page 60 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  • Maintaining adequate and accurate source documents and trial records that include  all 
pertinent observations on each of the site 's trial participants.  Source data should be 
attributable, legible, contemporaneous, original, accurate, and complete.  Changes to 
source data should be traceable, should not obscure the original entry, and sho uld be 
explained if necessary (eg, via an audit trail).  Source data are , in general , all 
information in original records and certified copi[INVESTIGATOR_122567], observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source 
documents (original records or certified copi[INVESTIGATOR_014]).   
• Verifying that data entries are accurate and correct by [CONTACT_108125].  
• Maintaining accurate d ocumentation (source data) that supports the information 
entered in the eCRF, or sent to a central vendor designated by [CONTACT_456], or as 
described in other study and data flow manuals.  
− Source documents provide evidence for the existence of the participan t and 
substantiate the integrity of the data collected.  Source documents are filed and 
available at the investigator 's site.  Example s of source documents are original 
documents, data, and records (eg , hospi[INVESTIGATOR_1097] ; electronic hospi[INVESTIGATOR_1097] ; 
clinical  and office charts ; labor atory notes ; memoranda ; participants ' diaries or 
evaluation checklists ; pharmacy dispensing records ; recorded data from 
automated instruments ; copi[INVESTIGATOR_27602] ; microfic hes; photographic negatives ; microfilm or  
magnetic media ; x-rays, participants ' files; and e-records/ records kept at the 
pharmacy, at the laboratories , and at medico -technical departments involved in 
the clinical trial).   
− Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records, 
depending on the study.  Current applicable medical rec ords must be available.  
• Sending participants ' data, either as unique samples, or copi[INVESTIGATOR_014], or photographs, to be 
evaluated centrally or analyzed c entrally, or both, by a qualified ve ndor designated by 
[CONTACT_456].  
− As required by [CONTACT_501051] r egulations and Incyte 's privacy 
policies, if any photographs of participants are to be taken, the photographs must 
be limited to the area of the face or the body that is strictly necessary and the 
photographs should be masked (ie, identifying features such  as eyes, mouth, scars, 
tattoos, or unique markings or features should be either obscured with a black bar 
or digitally pi[INVESTIGATOR_501009]) by a specially designated pho tography vendor prior 
to sending the photographs to Incyte or any other third -party vendors for analysis 
or further processing.  
Incyte Corporation  Page 61 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  • Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_501052].  
− Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The 
investigator must allow the auditors to review original source records and study 
documentation for all participants.  
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product.  The investigator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study -related documents.  The investi gator must immediately notify the sponsor 
when contact[CONTACT_147115].  
11.3. Data Quality Assurance  
The sponsor assumes accountability for actions delegated to other individuals (eg, contract 
research o rganizations). The sponsor or designee is responsible for the data management of this 
study, including quality checking of the data. Further, monitoring details describing strategy, 
including definition of study -critical data items and processes (eg, risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and analytical risk -
based monitoring), methods, responsibilities, and requirements, including handling of 
noncompliance issues, Protocol deviations, and monitori ng techniques (eg, central, remote, or 
on-site monitoring) are provided in the Clinical Monitoring Plan. 
Quality tolerance limits will be predefined in the Integrated Quality Risk Management Plan  to 
identify systematic issues that can impact participants ' safety, efficacy results and analysis, 
and/or reliability of study results. These predefined parameters will be monitored during the 
study and can be adjusted during the study upon data review. Important deviations from the 
quality tolerance limits and rem edial ac tions taken, including reporting to IRBs/IECs and health 
authorities if applicable, will be summar ized in the CSR.  
11.4. Data Privacy and Confidentiality  of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data pro tection laws 
and regulations. The investigator and the sponsor or its designee are responsible for ensuring that 
personal information is handled in accordance with local data protection laws (including but not 
limited to HIPAA and GDPR) as applicable, and the sponsor operates comprehensive data 
privacy and data security programs that are applicable to this study. Appropriate notice, or notice 
and consent (as may be required by [CONTACT_501053]), for collection, use, disclosure, 
Incyte Corporation  Page [ADDRESS_645302] been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and suffi cient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
• Failure of the investigator to comply with the Protocol , the requirements of the 
IRB/IEC or local health authorities, the sponsor 's procedures, or GCP guidelines . 
• Inadequate recruitment of participants by [CONTACT_093] . 
• Discontinuation of further study cream  development . 
Incyte Corporation  Page 64 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  12. REFERENCES  
Clinical Trial s Facilitation  and Coordination  Group . Recommendations related to contraception 
and pregnancy testing in clinical trials . 2020. 
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic 
dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am  Acad Dermatol 
2014;70:338 -351. 
Eucrisa (crisaborole ) [prescribing information]. [COMPANY_007] Inc; April 2020.  
Food  and Drug Administration. Draft  Guidance on Pi[INVESTIGATOR_031]. March 2012.  
Hanifin  JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 
(Stockh) 1980;92:[ADDRESS_645303] Working Group. A population -based 
survey of eczema prevalence in the [LOCATION_002]. Dermatitis 2007;1 8:82-91. 
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and 
severity index (EASI): assessment of reliability in atopic dermatitis EASI Evaluator Group. Exp 
Dermatol 2001;10:11 -18. 
Harrop J, Chinn S, Verlato G, et al. Eczem a, atopy and allergen exposure in adults: a 
population -based study. Clin Exp Allergy 2007;37:526 -535. 
Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of 
the prevalence and impact of skin conditions. J Invest Der matol 2014;134:1527 -1534.  
Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME . Treatment of atopic dermatitis  
with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone  cream. J Allergy Clin Immunol 
2020 a;145:572 -582. 
Kim BS, Sun K, Papp K, Ventura nza M, Nasir A, Kuligowski ME . Effects of ruxolitinib cream 
on pruritus and quality of life in atopic dermatitis: results from a  phase 2, randomized, 
dose-ranging, vehicle - and active -controlled  study. J Am Acad Dermatol 2020 b;82:1305 -1313.  
Leshem YA, Haj ar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score  
tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol  
2015;172:1353 -1357.  
Olumiant  (baricitinib) [prescribing information]. Eli Lilly and Company; December 2021.  
Opzelura (ruxolitinib) [prescribing information ]. Incyte Corporation; July 2022. 
Papp K, Szepi[INVESTIGATOR_22938], Kircik L, et al. Efficacy and safety of ruxolitinib cream for the 
treatment of atopic dermatitis: Results from 2 phase 3, randomized, double -blind studies.  J Am 
Acad Dermatol 2021: 85;863 -872. 
Pruritus Resources. Numerical Rating Scale (NRS). Accessed December 6 , 2021. 
http://www.pruritussymposium.de/numericalratingscale.html   
Rönmark  EP, Ekerljung  L, Lötvall  J, et al. Eczema among adults: prevalence, risk factors and 
relation to airway diseases. Results from a large -scale population survey in Sweden. Br J 
Dermatol  2012;166:1301 -1308.  
Incyte Corporation  Page 65 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  Ruxolitinib cream Investigator 's Brochure.  Wilmington, DE: Incyte Corporation.  
Spergel  JM. Epi[INVESTIGATOR_190057]. Immunol Allergy 
Clin North Am  2010;30:269 -280. 
Vinding  GR, Zarchi  K, Ibler  KS, Miller IM,  Ellervik  C, Jemec  GB. Is adult atopic eczema more 
common than we think? – A population -based study in Danish adults. Acta 
Derm  Venereol  2014;94:480 -482.  
Xeljanz (tofacitinib) [prescribing information]. [COMPANY_007] Inc; December 2021.  
Incyte Corporation  Page 66 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S AND DEFINITIONS  
Definitions  
WOCBP:  A woman who is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below) . 
Women in the following categories are not considered WOCBP:  
• Premenarchal  
• Premenopausal with 1 of the followi ng:a 
− Documented hysterectomy  
− Documented bilateral salpi[INVESTIGATOR_1656]  
− Documented bilateral oophorectomy  
• Postmenopausal  
− A postmenopausal state is defined as no menses for 12 months without an alternative medical  
cause.  
o A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state 
in women not using hormonal contraception or HRT.  However, in the absence of 12 months of 
amenorrhea, confirmation with 2 FSH measurements in the pos tmenopausal range is required.  
− Females on HRT and whose menopausal status is in doubt will be required to use [ADDRESS_645304] discontinue  HRT to allow confirmation of postmenopausal status 
before study enrollment.  
For male participants of reproductive potentialb 
The following methods during the Protocol -defined timeframe in Section  5.1 are highly effective:  
• Use of a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercourse with a WOCBP  who is not currently pregnant.  
• Vasectomy w ith medical assessment of the surgical success (verified by [CONTACT_8786] 's review of 
the participant 's medical records)  
• Sexual abstinencec 
− Abstinence from penile -vaginal intercourse  
The following are not acceptable methods of contraception:  
• Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus 
interruptus), spermicides only, and lactational amenorrhea method.  
• Male condom with cap, diaphragm, or sponge with spermicide.  
• Male and female condom used together.  
Note:  Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each epi[INVESTIGATOR_117492].  
Incyte Corporation  Page 67 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  For female participants who are WOCBP  
The following methods during the Protocol -defined timeframe in Section  5.1 that can achieve a failure 
rate of less than 1% per year when used consistentl y and correctly are considered as highly effective 
birth control methods:  
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulationd 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulationd  
− oral 
− injectable  
− implantablee 
• Intrauterine devicee 
• Intrauterine hormone -releasing systeme 
• Bilateral tubal occlusione 
• Vasectomized pa rtnere,f 
• Sexual abstinencec 
a Documentation can come from the site personnel 's review of the participant 's medical records, medical 
examination, or medical history interview.  
b If the male participant has a partner with childbearing potential , the partner should also use contraceptives.  
c In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from  heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the parti cipant.  
d Hormonal contraception may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.  
e Contraception methods that in the context of this guidance are considered to have low user dependency.  
f Vasectomized partner is a highly effective method of  avoiding pregnancy provided that partner is the sole sexual 
partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the 
surgical success.  
Source:  Clinical Trials Facilitation and Coordination Group [ADDRESS_645305] of clinical trials. The sponsor has issued the following Protoco l 
considerations to ensure participant safety is maintained and adequate benefit/risk analyses are 
applied relative to the completion of study procedures and maintaining the study cream  supply 
chain.  
Recognizing the flexibility required to manage the impac t of the pandemic on this clinical trial, 
additional details will be added as needed to respective study manuals and project plan 
documents and communicated to the investigative sites as needed.  
Number of Study Participants  
The evolving situation of the pa ndemic may result in a substantial number of participants ' early 
dropout from the study, which could affect the data integrity of the trial. Because of this risk and 
in order to mitigate it, the sponsor may decide to recruit additional participants in the study, 
beyond the expected number.  
Study Visits  
Remote Site Visit Guidelines:  
The evolving situation of the pandemic may lead to further travel restrictions and isolation 
requirements  that could impact the participant . Also, the investigator 's benefit/risk  assessment 
may determine it to be unsafe for participants to attend study visits at the investigational site. In 
such cases, the site staff may elect to pursue the following:  
• In order to minimize participant risk, study visits may be conducted via telemed icine 
modalities (phone or video calls). At a minimum, a review of AEs, concomitant 
medications, and study cream  compliance must be completed. Periodic on -site visits 
should be conducted whenever feasible, in particular  the critical on-site visits outlined  
below.  
• No investigator -assessed efficacy evaluations (ie, %BSA, IGA, or EASI)  can be 
performed via telemedicine (video call or phone call).  
• Laboratory sampling:  No off-site laboratory sampling will be allowed.  
Critical On-Site Visits:  
The visits outlined below must be performed in person  in order for the investigator  to assess 
the participant 's eligibility for the CT ( screening and baseline) and LTS (Week 8) periods, and 
the participant 's continued eligibility  throughout the LTS period , even if the date th at the 
participant eventually comes into the clinic deviates from the visit window.  
The visit window deviation must be documented, and the sponsor 's representative must be 
informed of when it is believed that the participant can come into the clinic. Furt her instructions 
will be provided if needed.  
Incyte Corporation  Page [ADDRESS_645306] be performed in person:  
• Screening  
• Day 1 (Baseline)  
• Week [ADDRESS_645307] Dispensing and Distribution  
In order to ensure the continuity of providing their participants ' clinical supplies within the 
constraints imparted by [CONTACT_47098], the site staff can decide to supply study cream  via 
shipment to participants.  
If the participant cannot attend a visit at the study site, adequate supplies of study cream  
determined by [CONTACT_501054] (eg, the study pharmacy staff) using a third -party service if duly 
authorized by [CONTACT_2299].  
The study site may use their own preferred courier, prov ided the courier adheres to certain 
standards (eg, use of personal protection equipment, maintenance of temperature -controlled 
transit environment), or one centrally contracted by [CONTACT_456].  
Clinical Trial Monitoring  
Study monitoring visits may be postpo ned due to documented COVID -19–related reasons; 
however, the site monitor will continue to employ off -site monitoring practices such as routine 
communication methods (eg, phone calls, e -mails, video visits) with the sites to get information 
on trial progre ss, subject status, and information on issue resolution. The study monitor may 
remotely review data entered into electronic systems such as the EDC for accuracy and 
completeness. If allowed by [CONTACT_427], remote source data verification may be 
imple mented with agreement of the principal investigator [INVESTIGATOR_312331], as applicable.  
If the study site monitor cannot be on -site to perform the final drug accountability for 
reconciliation purposes and the operation cannot be postponed, it may be performed by [CONTACT_501055]. Alternatively, it may be performed by a pharmacist from the hospi[INVESTIGATOR_501010]/data manager with suitable training. The study cream  can be destroyed in 
accordance with local practices, or returned to the sponsor b y the hospi[INVESTIGATOR_490532] , 
with sponsor approval.  
Other Considerations  
If necessary, direct contracts can be established with third -party local physicians to conduct 
activities related to the clinical management of participants for whom the investi gator is 
responsible and maintains oversight. In such situations, the investigator is required to provide the 
local physician with a delegation letter listing all delegated activities. The sponsor, through the 
Incyte Corporation  Page 70 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  study investigator or institution, will reimbu rse the local physician for the tests/procedures 
conducted outside of the standard of care.  
• In case of need, participants may refer to the local health care provider. Participants will 
be requested to obtain certified copi[INVESTIGATOR_501011]. 
The investigator/delegate will be requested to enter any relevant information into the 
EDC.  
• Should COVID -19–related restrictions be localized and have an effect on a limited 
number of sites, the affected sites may utilize direct contracting of third parties to support 
continuous study conduct (eg, home nursing services, couriers, etc).  
Reimbursement of Extraordinary Expenses  
The sponsor will arr ange to reimburse participants for any extraordinary expenses, keepi[INVESTIGATOR_312334] (eg, travel expenses for the local laboratory visit[s], the 
costs of local [nearby] laboratory tests).   
Incyte Corporation  Page 71 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  APPENDIX  C. PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Docum ent Date  
Amendment 1  30 NOV  2022  
Amendment 1 ( 30 NOV  2022)  
Overall Rationale for the Amendment  
The primary purpose of this amendment is to clarify  that Day [ADDRESS_645308] date is more than 2  weeks before 
Day 1 . Additional changes and clarifications are summarized below.  
1. Section 1, Protocol Summary ( Table 3: Schedule of  Activities: Continuous Treatment 
Period; Table 4: Schedule of Activities: Long -Term  Safety Period ); Section 6.1.1 , Study 
Treat ment Application Guidance ; Section 8.4, Pharmacokinetic Assessments (Table 10: 
Pharmacokinetic Blood and Saliva Sample Timing)  
Description of change: Removed the requirement for all morning study cream applications 
to be performed at the site, and revised to allow participants to apply either of the 2 daily 
doses at the site  after Day 1 . 
Rationale for change: To allow flexibility in  appointment time and to ease the burden on the 
participant and /or legal guardian . 
2. Section 1, Protocol Summary (Table 3: Schedule of Activities: Continuous Treatment 
Period); Section 8.3.5, Laboratory Assessments  
Description of change: Updated to clarify t hat Day 1 testing for serum chemistries and 
hematology will only be performed if the interval between Day 1 and the date of the 
screening laboratory tests is great than  2 weeks.  
Rationale for change: To clarify when Day 1 testing is required.  
3. Section 1, Protocol Summary ( Table 3: Schedule of Activities: Continuous Treatment 
Period; Table 4: Schedule of Activities: Long -Term  Safety Period ) 
Description of change: Added an assessment for Itch NRS eDiary compliance.  
Rationale for change: To improve compliance  of Itch NRS eDiary assessments.  
4. Section 1, Protocol Summary ( Table 3: Schedule of Activities: Continuous Treatment 
Period ); Section 8.4, Pharmacokinetic Assessments  (Table 10: Pharmacokinetic Blood 
and Saliva Sample Timing)  
Description of change: Revised the timing of the PK  blood  draw from morning to any time 
prior to study drug application but at least 4 hours after the previous application  of study 
cream . Also, provided guidance on blood draws from treated areas if no other acceptable 
blood draw areas a re available.  
Rationale for change: To decrease participant burden by [CONTACT_501056].  
Incyte Corporation  Page 72 of 72 
Protocol INCB [ZIP_CODE] -315 Am 1  Version 2 30 NOV  2022  
VV-CLIN -017192  CONFIDENTIAL  5. Section 3 , Objectives and Endpoints (Table 5: Objectives and Endpoints ) 
Description of change: Revised the exploratory endpoint s for the evaluation of efficacy of 
ruxolitinib cream in adolescents with AD . Remove d the Itch NRS score at each postbaseline 
visit, and add measurement timing for EASI scores, itch scores, and ITCH4 . 
Rationale for change:  To include  the analysis of  EASI  score s and also the daily itch and 
Itch NRS  response s at each postbaseline visit . 
6. Section 5.2 , Exclusion Criteria  (Criterion 12)  
Description of change: Deleted the exclusion criterion regarding the inability to draw blood 
for PK from any nonlesional areas . 
Rationale for change:  To allow for  drawing blood from a treated area provided the study 
cream is not applied at that  area during the previous application.  
7. Section 6.2, Preparation, Handling , and Accountability  
Description of  change: Revised study cream accountability at the conclusion of the study to 
reflect the process for handling remaining study cream for destruction at the site, or if local 
procedures do not allow on-site destruction, then shipment ba ck to the sponsor is allowed.  
Rationale for change: To reflect the current procedure for sample accountability following 
completion of the study.  
8. Section 6.6 , Concomitant Medications and Procedures  
Description of change: Clarified the timeframe s to be followed for recording in  the eCRF 
for non -AD medications and treatments and  for AD medications and treatment s. 
Rationale for change: To allow collection of prior AD medications and treatments for a 
12-month period.  
9. Section 6.6.2 , Restricted Medications and Procedures ; Section 6.6.3 , Prohibited 
Medications and Procedures  
Description of change : Updated  to allow the short -term use of systemic corticosteroids to 
treat acute AEs (eg, asthma) during the LTS period.  
Rationale for change : To allow for short -term treatment of a  concomitant illness which has 
no impact on safety or efficacy.  
10. Section [IP_ADDRESS] , Disease Charact eristics and Treatment History  
Description of change: Added acceptable forms of documentation that can be used to collect 
prior medical history for the use of t opi[INVESTIGATOR_501012].  
Rational e for change:  To provide guidance to the sites on the acceptable documentation for 
prior AD medical history.  
11. Incorporation of administrative changes. Other regulatory guidance and administrative 
changes have been incorporated throughout the Protocol and are noted in the redline version 
of the amendment.  
Signature [CONTACT_11032]-CLIN-017192 v3.0
Signature [CONTACT_11032]-CLIN-017192 v3.0Approval Task
Approver
 Biostatistics
30-Nov-2022 22:58:30 GMT[PHONE_006]
Approval Task
Approver
 Clinical Research Scientist
30-Nov-2022 23:06:47 GMT[PHONE_006]
Approval Task
Approver
 Inflammation &
01-Dec-2022 23:39:42 GMT[PHONE_006]
